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III Abstract  
Sepsis is a significant problem in the United Kingdom with diagnosis, management 
and prognosis proving difficult for clinicians. This is further exacerbated by the lack 
of sensitive and specific biomarkers for the disease and complications related with it 
(i.e. organ dysfunction).  The lack of biomarkers and efficacious therapeutic 
intervention is a result of inadequate understanding of this disconnect between 
murine and human sepsis on a molecular level and in vivo. In this analysis, 
comparison of molecular signalling pathways involved in inflammation has revealed 
a possible source for this disconnect. Comparative analysis of two well characterised 
murine models of sepsis (LPS and faecal peritoneal inoculation) has further 
demonstrated that the difficulty in recapitulating a similar environment of human 
sepsis in rodents widens the gap that the translational bridge must cross. Both models 
showed a similar level of change consistent with an acute systemic inflammatory 
response, but discrete differences show the superiority of the faecal inoculation as a 
reproducible, valid and more reliable model of murine sepsis. HMGB1 and 
cleaved/uncleaved CK18 have been shown to be accurate ways of monitoring the 
level of inflammation, necrosis and apoptosis in the literature. Their application to 
defined groups of ICU patients, who could potentially benefit from them, has shown 
that there is potential for a clinical application. Their use alongside currently used 
markers of liver function could enhance the overall picture that clinicians have when 
approaching these patients. However, further research is needed involving larger 
sample sizes and more scrupulous statically analysis before widespread application 
can occur.  
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1 General Introduction  
1.1 Sepsis  
Sepsis is a life threatening clinical condition defined as a systemic inflammatory 
response syndrome (SIRS) together with a demonstrable source of infection
1
. It is a 
major cause of admission to the Intensive care unit (ICU) and carries a high mortality 
rate of 30%
2
, that has been shown to increase in subsequent months after discharge 
from hospital
3
. Sepsis provides intensivists with significant difficulties regarding 
management and prognostication, and this is further exacerbated by the lack of 
specific and sensitive biomarkers available. Studies  have already identified the need 
for the investigation and integration of novel biomarkers with routine clinical 
chemistry, in order to better diagnose and improve the prognosis of this patient 
group.
4
  
1.1.1American College of Chest Physicians/Society of Critical care Medicine 
(ACCP/SCCM) definitions 1  
Up until the construction of a general census on the definitions surrounding SIRS, 
sepsis and related syndromes, there was often diagnostic confusion and misuse of 
terms in the literature. The ACCP/SCCM set out to construct a clear set of definitions 
that would allow clinicians and researchers to better diagnosis patients and improve 
inclusion criteria into studies. Initially they defined the clinical parameters required 
for the diagnosis of SIRS, an inflammatory process independent of an infectious 
cause, but related to other aetiologies (i.e. burns, trauma etc.). The committee then 
developed four recommendations which outlined the terminology surrounding sepsis 
and sepsis syndromes. Their recommendations are summarised in table 1.1. 
1.1.2 Epidemiology 
In a large multi-centred cohort study Alberti et al 
5
 described that one fifth of patients 
on admission to ICU had evidence of infection, along with one third of patients who 
were considered to be “long stay” patients. Altogether eighty per cent of these 
patients showed evidence of an inflammatory response and would fit in to the 
ACCP/SCCM definition of sepsis
1
. This study also identified that the major sources 
of infection where respiratory, abdominal, urinary and bloodstream, which is similar 
to what has been reported before. However, a further study in the UK reported that 
the majority of patients admitted to ICU with severe sepsis where non-surgical cases 
suffering with cardiovascular or respiratory aetiologies
6
. Gram negative bacilli (in 
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45% of patients) and Gram-positive cocci (in 37% of patients) were identified as 
common causative organisms for infection
5
.  
The incidence of severe sepsis remains fairly consistent between studies and is 
reported as ten cases per 100 ICU admissions 
7
. The UK, however, has been noted to 
have a higher incidence (51 per one 100, 00 population per year admitted to ICU 
with severe sepsis
6
). This has been attributed to the fact that other countries have a 
lower threshold for admission to ICU, even before patients require organ or 
ventilator support, whereas in the UK patients that are admitted to ICU frequently 
present with sepsis and multiple organ failure 
7
. Multiple organ failure is associated 
with a poorer outcome, and this is reflected in an ICU mortality rate for severe sepsis 
of 35% and overall hospital mortality rate of 47% in the UK
6
.  
1.1.3 Financial Burden  
Angus et al (2) reported that the estimated burden of severe sepsis in the United 
States (US) was sixteen point seven billion dollars per annum (roughly ten point 
seven British pounds). Studies estimating the cost in the UK are sparse but scaling 
this down for the UK population reveals estimated costs of two point six eight billion 
British pounds. These figures demonstrate the need for further research into novel 
ways of diagnosing and prognosticating these patients in order to reduce costs and 
overall National Health Service (NHS) burden. 
1.1.4 Pathophysiology of Sepsis  
As described by the ACCP/SCCM
1
 Sepsis is the combination of SIRS with a 
demonstrable source of infection. Gram negative bacilli and Gram-positive cocci 
have already been described as causative agents in the provocation of an initial 
inflammatory response
5
. Inflammation comprises a large portion of the body’s innate 
immune response to infection; so is considered a normal bodily function. 
Historically, the exaggerated response seen in sepsis, and severe sepsis severity, has 
been made responsible for the disease. The idea of sepsis as an exaggerated 
inflammatory response was based on the observation that lipopolysaccharide (LPS), 
a component of  gram-negative bacteria, elicits a sharp increase in pro-inflammatory 
cytokines, such as TNF-α, IL-6 and IL-18. Consequently, animal models of 
endotoxaemia have been widely used to better understand the pathophysiology of 
sepsis.  The significantly raised levels of cytokines, in particular TNF-α, led to the 
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hypothesis that inhibition of these cytokines, could improve outcome. Although this 
was the case in animal models
9
, failure of these antagonistic drugs in humans was at 
least partly due to the different cytokine profile seen in humans during sepsis 
10
. 
Recent studies suggest that although  there is an initial pro inflammatory stage in 
human sepsis, patients with a prolonged, chronic state of inflammation often progress 
into a subsequent anti-inflammatory immunodeficent state referred to as 
“immunoparalysis”11. Patients with immunoparalysis often die of secondary 
nosocomial infection as a result of an ineffective immune response. This has been 
attributed to the over-production of interleukin 10 (IL-10) and decreased splenocyte 
production of Interferon gamma (IFN-γ)12. This counter-regulatory reaction to the 
over-zealous SIRS seen in sepsis is referred to as “Compensatory anti-inflammatory 
response syndrome” or CARS.   
1.1.5 Further research  
With an increasing cost on ICUs around the UK, the importance of diagnosing, 
treating and prognosticating sepsis is becoming more important.  In order to do that, 
a better understanding of the molecular pathways involved in inflammation need to 
be researched. As such, more appropriate models of experimental sepsis need to be 
developed in order to discover more efficacious and relevant biomarkers that could 
aid in the diagnosis and treatment of the disease. This work is designed to give an 
overview of the key inflammatory signalling pathways and events involved in the 
development of an immune response, demonstrating on a molecular level the 
dichotomy that can exist between human and murine sepsis.  Current models of 
experimental sepsis will be investigated in order to evaluate current understanding 
and the successfulness of experimental models in replicating the human disease. This 
combined with the analysis of new biomarkers in human serum will give a 
translational overview of developments in the research of sepsis,  highlighting the 
difficulties that are faced, and the clinical benefits of continuing and advancing 
research in this area. 
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Recommendation 1 “SIRS should describe the inflammatory process independent 
of its cause.” More than one of the flowing clinical criteria 
should be met in order reach a definition of SIRS:  
 Body temperature <36 or >38 degrees Celsius  
 Hear rate .90 beats per minute  
 Tachypnoea >20 breaths per minute or arterial partial 
pressure of carbon dioxide less than 4.3 kPa (32mmHg) 
 White blood cell count <40000 cells/mm or >120000 
cells/mm or the presence of >10%  immature 
neutrophils (band forms 
 
Recommendation 2  “Whenever SIRS is the result of a confirmed infectious process it is 
sepsis” 
Recommendation 3 I. “Infection shall be defined as a microbial phenomenon 
characterised by an inflammatory response to the presence of 
a micro-organism or the invasion of normally sterile host 
tissue by those organisms.” 
 
II. “Bacteraemia is the presence of viable bacteria in the blood; 
the presence of virus’ or fungi should follow on from this 
(i.e. viraemia etc).” 
 
III. “Septicaemia should be eliminated from usage due to its 
misuse and confusion.” 
  
Recommendation 4 I. “Severe sepsis will be classified as sepsis with the presence 
of organ dysfunction or a hypoperfusion abnormality (i.e. 
lactic acidosis) or hypotension.” 
 
II. “Sepsis induced hypotension should be defined as a systolic 
pressure of <90mmHg or a reduction by 40mmHg from 
baseline, in the absence of other causes.” 
 
III. “Septic shock is a subset of severe sepsis and is defined as 
sepsis induced hypotension, persisting despite adequate fluid 
resuscitation along with the presence of hypoperfusion 
abnormalities or organ dysfunction.” 
 
Table 1.1: Summary of the recommendation from the ACCP/SCCM consensus 
committee paper 
1
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1.2 The human immune system and the inflammatory response  
The human immune system can be divided into two components; innate and acquired 
immunity. Acquired immunity is characterised by the production and distribution of 
B and T lymphocytes involved in memory and antibody production. Innate immunity 
is comprised primarily of the functions of leucocytes in the peripheral blood, namely 
the inflammatory response.  Inflammation is the body’s first line of defence to 
invasion. The majority of the process involves the release of chemical mediators and 
cytokines which come from plasma proteins or cells including mast cells, platelets, 
neutrophils and monocytes/macrophages. Chemical mediators bind to specific 
receptors on target cells and can increase vascular permeability and neutrophil 
chemotaxis, stimulate smooth muscle contraction, have direct enzymatic activity and 
induce pain or mediate oxidative damage.  
1.2.1Damage and Pathogen associated molecular pathways (DAMPs & PAMPs) 
When invading organisms enter the body their specific groups or motifs of 
exogenous proteins are detected by the immune cells, these are referred to as 
Pathogen associated molecular pathways or “PAMPS”. These along with 
endogenous alarmins (groups of proteins that are released by immune or damaged 
cells) are referred to as damage associated molecular pathways “DAMPS”. DAMPS 
are the crucial first step in the development of an inflammatory response. While  
DAMPS have an exogenous origin, alarmins  arise from various endogenous sources 
including release following non-programmed cell death  (i.e. not apoptosis); 
specialised immune cells can also release them through an endoplasmic reticulum 
(ER)- Golgi pathway 
13
.  
DAMPs act on immune cells to provoke an inflammatory response through a group 
of proteins on the cell surface called Toll-Like receptors (TLR). TLRs are type I 
transmembrane proteins with an extracellular domain, consisting of a leucine-rich 
repeat (LRR) domain, and a cytoplasmic domain homologous to the cytoplasmic 
domain of the human interleukin (IL)-1 receptor 
14
. Medzhitov et al 
14
 not only first 
described the Toll proteins, but also identified that TLR 4 was the main receptor for 
LPS  and led to downstream activation of transcription factor NFκB (nuclear factor 
kappa-light-chain-enhancer of activated B cells). Once activated the TLRs interact 
with adaptor proteins resulting in a downstream activation of signalling cascades, 
leading to activation of NFκB, which controls induction of pro-inflammatory 
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cytokines and chemokines 
15
. Further studies
16
; have shown that there is a significant 
up-regulation of TLR 2 and 4 during human and experimental sepsis. Eleven TLRs 
in total have been identified; 1,2,4,5 & 6 mainly detect bacterial products while 3, 7 
& 8 are involved in viral detection. Table 1.2 from Tsujimoto et al 
17
 describes the 
various exogenous and endogenous ligands that signal through TLRs.  
1.2.2 Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) 
signalling pathway  
In humans, the NFκB signalling pathway is a group of five members; NFκB1 
(p105/p50), NFκB2 (p100/p52), RelA (p65), RelB and c-Rel which collectively have 
been shown to be ubiquitously expressed.  Rel-related transcription factors serve as 
critical regulators for the inducible expression of several genes
18, 19
. Each of the five 
proteins contains a rel-homology domain (RHD), which is a conserved amino acid-
terminal region containing a nuclear localisation sequence (NLS) important in gene 
transcription.  Inactivation of the NFκB signalling pathway is through complexing of 
the RHD with Inhibition of NFκB (IκB) proteins resulting in inactivation of the NLS. 
Inactive NFκB proteins reside in the cytoplasm of cells complexed with IκB. 
Degradation of this complex through phosphorylation of IκB by IκB kinase (IKK) 
complex is under the mediation of TLR receptors. Activation allows NFκB to 
translocate from the cytoplasm to the nucleus, inducing target gene transcription 
through the NLS. As discussed previously, the TLRs are stimulated by DAMPs and 
pro-inflammatory cytokines. The most common signalling pathway of NFκB 
translocation is described as the “classical pathway” and is summarised in figure 1.1. 
Activation of this pathway mostly leads to the translocation of the p50-p65 
heterodimer and increased transcription of genes coding for cytokines needed to 
mount an inflammatory response. The composition of the NFκB dimers exerts 
substantially different effects on gene transcription 
20
. 
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1.2.3 Key pro-inflammatory cytokines in the development of Inflammation  
There are three important cytokines that are produced and released from activated 
immune cells (typically mononuclear cells) as part of the initial pro-inflammatory or 
“acute-phase” response; these are IL-1, IL-6 and TNF-α. These molecules are the 
earliest to be released and are followed later by IL-12, IL-15, IL-18 and an array of 
other molecules (i.e. chemokines, lipid mediators and oxygen free radicals) 
21
. Table 
1.3
22-30
 summarises the major cytokines involved in the inflammatory response; 
including information about their release, where they act and the response they evoke 
(with relation to inflammation only).  
TNF-α has been identified as a crucial mediator in the development of septic shock 
in animal models 
9
 and has a similar role in patients  
31
. A poorer outcome of patients 
with meningococcal sepsis was associated with higher levels of the cytokine. It has 
an important synergistic relationship with IL-1
25
. IL-6 alone does not appear to have 
a causal effect in provoking an inflammatory response but combined with IL-1 and 
TNF-α, potentiates it25. Significant rises in serum IL-6 also correlate with poorer 
outcome in septic patients
10
. The initial rise in pro-inflammatory cytokines is 
accompanied by a rise in compensatory anti-inflammatory cytokines and high serum 
levels have also been correlated with a poorer outcome 
32
. IL-1, IL-6 and TNF-α are 
all referred to as “acute phase” cytokines, as they are the first cytokines released in 
response to invasion. IL-12, 15 & 18 are “late phase”, and along with the more 
recently characterised cytokine Human mobility group box protein-1 (HMGB1) are 
involved in maintaining and regulating the state of inflammation. 
1.2.4 High mobility group box protein as an inflammatory cytokine 
HMGB1 is a 30KDa inflammatory cytokine and nuclear transcription factor that has 
a delayed onset of activation in comparison to other pro-inflammatory cytokines. Its 
nomenclature is derived from its high mobility in electrophoretic polyacrylamide 
gels
33
. It is a 214 amino acid long protein that has specific regions including an A 
box, B box, acidic tail and 43 lysine residues – these all contribute towards the 
molecule’s varied functions 34. Research has shown that HMGB1 release is largely 
divided into two pathways, either active secretion by monocytes as a pro 
inflammatory cytokine or passive release from apoptotic and necrotic cells 
35
. Its 
action, in inflammation, is largely on TLR receptors, most importantly TLR 2 and 
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TLR 4
33
. As mentioned above, this pathway leads to the activation of NFκB, which is 
crucial for the transcription of other pro-inflammatory cytokines such as IL-1, IL-6 
or TNF-α.  In vitro analysis showed that after stimulation with LPS measurable 
levels of HMGB1 mRNA could be detected after 24 hours
36
. Mass spectroscopy has 
demonstrated that depending on the mode of release various “sub-forms” of HMGB-
1 exist. Necrosis releases HMGB-1 in a reduced form that mediates the massive 
release of TNF-α, which is shown to be lethal in mice models37. However, cells that 
undergo apoptosis do not cause a release of TNF-α; and this is largely due to the 
oxidation of cysteine at position 106 on the B box arm of the HMGB-1 molecule
38
. 
Therapeutic antagonism of HMGB-1 using polyclonal antibodies against HMGB1 
reduces severity and fatality of sepsis in several mice models
39. 
1.2.5 Drug toxicity and inflammation  
Acetaminophen (APAP) hepatotoxicity because of overdose is the most common 
cause of acute liver failure in the western world 
40
. Metabolic activation of APAP 
and toxic metabolite formation, mitochondrial dysfunction, oxidant stress, 
peroxynitrite formation and nuclear DNA fragmentation are critical intracellular 
events in hepatocytes. However, the early cell necrosis causes the release of a 
number of mediators such as high-mobility group box 1 protein  (DAMPs), which 
can be recognized by toll-like receptors on macrophages, and leads to their activation 
with cytokine and chemokine formation. Although pro-inflammatory mediators 
recruit inflammatory cells (neutrophils, monocytes) into the liver, neither the 
infiltrating cells nor the activated resident macrophages cause any direct 
cytotoxicity
41
. Larson et al concluded that the extensive sterile inflammatory 
response during APAP hepatotoxicity is predominantly beneficial by limiting the 
formation and the impact of pro-inflammatory mediators and by promoting tissue 
repair. 
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 Ligands 
TLR Exogenous  Endogenous  
1 Triacyl lipopetide  
2 Peptidoglycan lipoprotein Necrotic cells  
3 Double-stranded  RNA HSPs (HSP-60, HSP-70,Gp-96) 
Biglycan 
4 LPS 
 
Taxol (mouse TLR-4 only) 
Extra domain A-contain fibronectin 
 
 Fibrinogen  
 Polysaccharide  fragments of heparin 
sulphate 
 Oligosaccharides of hyalouronic acid  
 ß Defensin 2 
 Oxidized low-density lipoprotein 
 HSPs 
 Surfactant protein A in the lung 
 epithelium 1 
 Neutrophil elastase 
 High mobility group box 1 protein 
 Biglycan 
 
5 Flagellin  
6 Diacyl lipopeptide   
7 Single –stranded RNA  
8 Single – stranded RNA  
9 Unmethylated CpG DNA Chromatin IgG complex 
10 Unkown  
11 Uropathogenic Escherichia Coli (E-Coli)  
Table 1.2: Table taken from Tsujimoto et al 
17
. Table showing exogenous and 
endogenous ligands that act on TLRs. IgG indicates immunoglobulin; TLR, toll-like 
receptor; HSP, heat shock protein; CpG, deoxy-cystidylate-phospate-deoxy-
guanylate. 
 
 
 
 
 
 
 
 
 
 27 
 
Figure 1.1: Figure taken from Bonizzi et al 
19
 NFκB “Classical” signalling pathway. 
Various endogenous and exogenous ligands act on the TLRs causing a signal 
transduction that results in the degradation, phosphorylation and ubiquitination  of 
IκB by the IKK complex. The final step involves the release of the NLS on NKκB 
leaving it free to translocate to the nucleus and induce transcription of mRNA which 
can go on to code for various cytokines, chemokines, enzymes and adhesion 
molecules. (*IκB, I-kappa-B, IKK-IκB kinase, NLS, nuclear localization signal). 
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Table 1.3: Table showing the major pro-inflammatory cytokines including 
information about their release, action and response in relation to the inflammatory 
response only 
22-30
 
 
Cytokine  Primary Release  Action  Response 
Early or “Acute phase” Cytokines 
TNFα Macrophages, 
Monocytes &  
Dendritic cells  
TNF Receptor family: 
TNFR1 – found in most 
tissues whereas; 
TNFR2 – is only expressed 
in immune cells 
Endogenous pyrogen 
Activation of NFκB signalling and Mitogen-
activated protein kinase pathways which lead to 
production and release of cytokines. TNF has 
also been shown to be important in  
cell death signalling 
IL-1α Macrophages, 
Monocytes, & 
Dendritic cells  
IL-1 Receptor family: 
Type I:  Proinflammatory  
Type II: Anti-inflammatory 
through competitive IL-1 
binding. 
Endogenous pyrogen 
IL1 results in increased gene expression in the 
cell of release and neighbouring cells.  
IL I-induced production of itself, IL 2, and B 
lymphocyte growth factors augments the 
immune response to antigens whereas IL 1-
induced interferonγ production 
results in an anti-inflammatory action. 
IL-1ß 
IL-6 Macrophages 
and Activated T 
cells  
IL-6 Cell surface type 1 
cytokine receptor complex 
(gp80 and IL-6Rα sub units)  
Induces differentiation of activated B cells; 
culminating in the production of 
immunoglobulin.  
Stimulates proliferation of thymic and 
peripheral T cells and induces differentiation 
into cytotoxic T cells. 
Late cytokines  
IL-12  Macrophages, 
Monocytes, 
Neutrophils & 
Dendritic cells  
IL-12 Receptor which 
consists of a IL-12ß2 subunit 
that is only found on 
activated T cells. 
Most of IL-12 pro-inflammatory effects are 
mediated through IFN-γ. It induces increased 
proliferation and colony formation of Natural 
killer and T cells as well as increasing their 
cytoxicity and expression of cytotoxic 
mediators. It stimulates the differentiation of 
cells into those that produce cytokines. 
IL-15 Macrophages, 
Monocytes & 
Dendritic cells 
IL-15 Receptor Natural killer cell proliferation.  
IL-18 Macrophages, 
Monocytes, & 
Dendritic cells 
IL-18 Receptor heterodimer 
consisting of a α &ß subunit. 
Like IL-12, some of the effects of IL-18 are 
mediated through IFN-γ production. It is also 
important in T and Natural Killer cell 
maturation along with production of 
inflammatory cytokines. 
HMGB1 Macrophages, 
Monocytes  
TLR 2 & 4 Activation of NFκB and production of 
cytokines. Upregulation of endothelial adhesion 
molecules, stimulation of epithelial cell barrier 
failure, and mediation of fever and anorexia 
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1.3 Animal models of sepsis  
Sepsis in humans often has polymicrobial aetiology, along with often being 
heterogeneous in focus. These factors seem to be the major difficulties when similar 
conditions are attempted to be recreated in some experimental animal models 
42
 . In 
order for experimental sepsis to be translatable to clinical medicine, it needs to 
replicate the key events seen in humans to include the hemodynamic and 
immunological changes seen. Marshall et al 
43
 concluded that although there was no 
ideal model of sepsis, various models offer different recapitulations of discrete 
features of the disorder.  Redl et al 
44
 suggested that  the most appropriate  model will 
depend largely on aspect of interest. The widely used endotoxin  model  is now being 
replaced by those that induce an inflammatory response more similar to the  
“polymicrobial” intra-abdominal sepsis event in humans, i.e. caecal ligation and 
puncture (CLP), colon acendens stent procedure (CASP) and various methods of 
faecal or tissue inoculation in the peritoneal cavity. Four key papers comparing and 
contrasting the major models of sepsis are summarised in Table 1.4 
45-48
 
1.3.1 Translational disconnect  
Mathiak et al 
45
 demonstrated that by  intra-peritoneal inoculation of E. coli the 
human cytokine profile of sepsis could be replicated in a rat. However, inoculation 
with murine faecal material induced changes in mice which mimicked more 
appropriately the metabolic, hormonal and energy derangements observed in human 
sepsis. More advanced techniques include CLP and CASP; CLP was shown to be 
superior to LPS in replicating a consistent model
46, 47
, as LPS induces a sharp, but 
transient rise in cytokines that is usually not sustained and different to that seen in 
humans. Maier et al
46
 found CASP to be a superior model compared to CLP in that it 
was more consistent with the pathological diffuse abdominal peritonitis, whereas 
CLP mice were found to develop intra-abdominal abscesses after the procedure. 
Problems with techniques such as CLP or CASP include the time for training and 
skills required for the actual procedure. Other worries surrounding the use of these 
models involve reproducibility, variability and also a so called “double-hit” of 
cytokines, where a surgical procedure will see a rise in cytokines independent of the 
intervention intended to causes sepsis. Gonnert et al 
48
 identified that in using a batch 
of stool for peritoneal inoculation, reproducibility was possible and variability 
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between experiments could be reduced. Experimental modelling of sepsis is largely 
accepted to be the main failure of efficacy of developed therapeutic agents. 
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Table 1.4: Summary of four major papers that investigate different models of murine sepsis (43-46)
Study  Year Methods Results Conclusion  
Caecal ligation and puncture 
(CLP) versus colon ascendens 
stent peritonitis (CASP): Two 
distinct animal models for 
polymicrobial sepsis.  
Maier et al   
SHOCK,  21(6); 505–511, 2004 46 
2004 8-12 week old female mice were sorted into two 
groups and given either of the two interventions: 
 CASP – a venous catheter (venflon) was 
inserted into the ascending colon and 
contents were allowed to flow into the 
abdominal cavity. 
 CLP – the cecum was ligated with 15mm 
of prolene and then punctured using a 
needle. 
Comparison of the models suggests that CLP results in 
the formation of an intra-abdominal abscess, Whereas 
diffuse peritonitis was only observed in the CASP 
model.  Evaluation of the abdomen of CASP mice 
after 24 hours revealed that there is still an opening in 
the luminal site with increasing signs of systemic 
infection and inflammation. In CLP only moderate 
levels of increase were found. CASP mice also 
demonstrated earlier involvement of the lungs and 
liver.  
The closer the model is adapted to 
human disease, 
the more reliable will be the results. 
Thus, for evaluation of 
new treatment approaches for 
diffuse peritonitis, the CASP 
model appears advantageous over 
CLP, whereas for other 
intra-abdominal infections such as 
abscesses, the CLP model 
should be preferred. 
Comparison of the mortality and 
inflammatory response of two 
models of sepsis: 
lipopolysaccharide versus caecal 
ligation and puncture. 
Remick et al  
SHOCK 13 (2);110-116, 2000 
47
 
2000 Female mice were sorted into two groups and 
given either of the interventions: 
 CLP - the caeum was ligated with prolene 
1cm before the distal end. Punctures were 
made using a needle. 
 LPS – mice were injected. 
intraperitoneally with 1ml of normal 
saline containing 250µg of  E-coli type 
(0111:B4; sigma) LPS. 
LPS and CLP appear to be duplicate models of sepsis, 
with nearly equivalent lethality and loss of activity. 
LPS causes a deeper decline in peripheral lymphocyte 
count compared with CLP. LPS causes a more rapid 
release of cytokines over the initial period post dosing 
and then begin to decline. 
Although the mortality and the 
morbidity of the two models were 
similar, the inflammatory responses 
evoked are distinctly different.  
An improved clinically relevant 
sepsis model in the conscious rat 
Mathiak, G et al  
Critical Care Medicine 
28(6); 1947-1952, 2000 
45
 
2000 Male Sprague-Dawley rats where anesthetised and 
their peritoneum was inoculated with a human 
derived fibrin-thrombin clot that had been 
incubated with a strain of E-coli isolated from the 
respiratory sputum (capsulated and serum resistant, 
similar to the gram negative sepsis in humans). 
Control rats were given a sham inoculation. The 
rats were then observed for three days   
This model replicated the cardiac abnormalities seen 
in human sepsis (i.e. increase in cardiac output). Mice 
became thrombocytopenic which is also a feature of 
human sepsis. TNF elevation was only marginal at the 
higher dosed implantation of clots compared with 
endotoxin 
This model of peritonitis sepsis 
evokes an inflammatory response 
similar to that of human sepsis. 
This is superior to the commonly 
used endotoxin model and in 
addition is reproducible and low 
cost.  
Characteristics of clinical sepsis 
reflected in a reliable and 
reproducible rodent sepsis 
model 
Gonnert et al 
J sur res 170(1);123-134,2011
48
 
2011 Male Wistar rats were given an intra-peritoneal 
injection of faeces from a pooled batch consisting 
of faces from three healthy vegetarians. Intensive 
monitoring followed involving insertion of a 
central jugular vein catheter. A sham experiment 
involving the IP injection of saline was also given. 
None of the septic animals survived 40hours after 
induction of sepsis. Animals displayed clinical signs 
of sepsis 2hours after induction. Antibiotic treatment 
resulted in a 50% increase in survival. Markers of 
sepsis correlated with organ dysfunction and 
histopathological changes. 
This model provided a reproducible 
and reliable model of polymicrobial 
sepsis that was quantifiable and 
similar to key clinical and 
molecular changes seen in human 
sepsis. 
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1.4 Sepsis and organ dysfunction 
Organ dysfunction is a common occurrence in patients with severe sepsis admitted to 
ICU, and these patients often require organ replacement therapies or vital organ 
support. The mechanisms for the dysfunction is largely attributed to the huge 
increase in systemic cytokine and mediator release which results in immune 
dysregulation, hormonal alterations, metabolic changes, activation of the coagulation 
cascades, and mitochondrial, micro-vascular, and epithelial dysfunction 
49
. Most 
tissues contribute to the release of cytokines in inflammation. The differences in 
organ response lead to the so-called compartmentalisation of the inflammatory 
response and influence the organ’s ability to function during sepsis. The significance 
of compartmentalisation in sepsis is demonstrated by the observation that in the 
broncho-alveolar lavage fluid of patients with adult respiratory distress syndrome   
lower levels of anti-inflammatory cytokines were associated with poorer outcome 
50
; 
whereas high plasma levels of inflammatory and anti-inflammatory cytokines were 
associated with poorer outcome 
51
. The liver has also been identified as a key organ 
for dysfunction during sepsis. Gonnert et al 
48
 reported that an early increase in 
markers associated with hepatocellular and cholestatic dysfunction is observed in 
experimental sepsis and sinusoidal and endothelial-leukocyte changes have been 
confirmed by histopathology.  
Recently, over-activation of neutrophils has been identified as a major contributing 
cause of organ dysfunction 
52
. The activation and increase in numbers of neutrophils 
provides a functional paradox within patients with sepsis: High numbers of activated 
neutrophils are needed to clear bacterial products, but collateral tissue damage by 
reactive oxygen species and cytokine release also increases. Hence, timely removal 
of neutrophils by apoptosis is key in the resolution of the inflammatory response to 
avoid leakage of intra-cellular products from necrotic cells however, this mechanism 
appears to be impaired in systemic patients with SIRS 
53
. Apoptosis is the process of 
programmed cell death 
54
.  Patients with SIRS have an impaired cellular apoptotic 
pathway 
53
. Therefore being able to assess and quantify the level of apoptosis could 
prove useful in giving an indication of prognosis and severity of disease.  
Keratins are proteins which are found in the cytoskeleton of epithelial tissue. 
Recently cytokeratin 18 (CK18), a protein of the larger Keratin family, has been 
discovered as a marker of apoptosis and necrosis. During necrosis, the cytosolic pool 
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of soluble CK18 is released, whereas apoptosis is associated with significant release 
of caspase-cleaved CK18 fragments. These results suggested that assessments of 
different forms of CK18 in patient sera could be used to examine cell death modes. 
One study 
55
 has already shown that single serum analysis of septic patients 
demonstrates higher levels of caspase-cleaved CK18 versus serum of other patients 
admitted to ICU. The study concluded that CK18 could be useful for monitoring 
endothelial function in sepsis. Further studies have demonstrated that mutations in 
CK18 predispose to liver disease through unregulated apoptosis and fibrosis. This 
mutation could potentiate the pre-existing susceptibility to sepsis that comes with 
different forms of liver disease,  in particular liver cirrhosis 
56
. As HMGB1, similar 
to CK18, is not organ specific, its use as part of a screening panel may help to 
diagnosis and prognosticate sepsis in ICU patients more efficiently and in a more 
specific patient group help to differentiate liver dysfunction due to sepsis from 
decompensation in patients with cirrhosis (i.e. secondary to alcoholic liver disease) 
due to non-infectious causes, respectively. 
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1.7 Hypothesis and Aims 
Translational medicine is important in the development of new treatments, and 
making sure these treatments are founded on sound biological science. This work 
aims to use various techniques and histopathological analysis in order to examine 
key components of the human inflammatory process and sepsis, looking at how 
experimental data translates towards the clinical process. Two cell lines, THP1 
(human monocytes) and RAW 264.7 (murine macrophages), are used to investigate 
inflammatory signalling pathways in the development of an inflammatory response, 
namely the activation of TLRs and NFκB. These experiments will allow a 
comparison of human and murine inflammatory responses and contribute towards an 
explanation for the translational disconnect between murine and human sepsis on a 
molecular level. Furthermore, comparing the widely used LPS model with a more 
reproducible polymicrobial intra-peritoneal faecal inoculation model will allow for 
an in-depth histopathological analysis of tissues, in order to examine the differences 
between the two distinct inflammatory insults and investigate which offers an 
experimental model that is more similar to human sepsis. Lastly, two proteins, 
HMGB1 and CK18, will be analysed in patient serum to see if they offer any 
potential as biomarkers of sepsis and in particular liver dysfunction associated with 
sepsis.  
Three hypotheses have been constructed in order to meet the aims of the thesis. 
These are: 
1. LPS-induced responses depend on cell type and species: THP1 and RAW 
264.7 cells dosed with LPS will exhibit varying levels of activation of the 
NFκB pathway (via the TLR receptor) and subsequent nuclear translocation 
of the P65 subunit, depending on the concentration of LPS. 
2. LPS induces histopathological changes different from faecal inoculation: 
Histopathological analysis of cells from Mice dosed IP with LPS or faecal 
suspension will show differing levels of tissue recruitment and damage of 
various tissues compared to controls and those dosed with acetaminophen. 
3. Serum levels of potential sepsis biomarkers HMGB1 and CK18 vary with the 
underlying liver condition: Two groups of critically ill patients will be 
compared: 1. Patients with sepsis and no history of liver disease 2. Patients 
with sepsis and known liver disease. Results will be compared to healthy 
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volunteers (controls) and patients admitted to ICU without sepsis or 
underlying liver disease.   
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In vitro analysis of cell 
signalling pathways in sterile 
inflammation 
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2. In vitro analysis of cell signalling pathways in sterile 
inflammation  
2.1 Introduction  
2.1.1Sterile inflammation and the NFκB pathway 
Sterile inflammation is defined as a group of stimuli that are non-infectious (absence 
of living micro-organism)  but ultimately lead to the same downstream vascular and 
cellular manifestations of inflammation 
57
. These stimuli can be largely divided into 
injurious, irritant, or antigenic. LPS, although derived from Gram negative bacteria, 
are classified as antigenic and irritant so the immune response elicited in vitro is 
therefore classified as “sterile inflammation”. Although they are not live stimulants, 
sterile inflammation elicits a similar pattern recognition and inflammatory response 
to “infectious” inflammation 58. Inflammation forms an important part of the human 
innate immune system and as discussed (section 1.2), activation of the NFκB 
signalling pathway through the mediation of the TLRs is an important pathway for 
the production of inflammatory cytokines (see 1.2.2). The classical pathway is 
described in figure 1, however Bonizzi et al 
19
 also describe an “alternative pathway” 
which is dependent on the IKKα  homodimer and translocation of different members 
of the Rel protein family. The pathway is described in figure 2.1. 
2.1.2 Alternative NFκB pathway  
Activation of both NFκB pathways is the result of IKK mediated, phosphorylation 
induced degradation of the IkB inhibitor, which allows the proteins to translocate to 
the nucleus. A comparison of the two pathways shows that the classical pathway is 
dependent on the IKKα- IKKβ heterodimer whereas the alternative pathway is 
dependent on the IKKβ homodimer.  In contrast to the pro-inflammatory role of the 
classical pathway, the alternative pathway has been described as having a significant 
role in the maintenance and development of lymphoid organs and adaptive immune 
system 
59
, more specifically the survival and maturation of B lymphocytes 
60
. The 
classical NFκB pathway is mainly based on the translocation of p65/p50 dimers, 
whereas the alternative pathway involves other dimers, including p52, which are 
released following processing of precursors such as p100 – a progression exclusively 
seen in the alternative pathway 
61
. 
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2.1.3 The role of the monocyte in inflammation  
Monocytes are bone marrow (myeloid cell line) derived immune cells that serve to 
replenish macrophages in the body as well as having the ability to differentiate into 
dendritic cells and osteoclasts. They circulate in the blood for around 2-3 days as 
well as being stored in the cords of Billroth in the red pulp of the spleen. Due to their 
low numbers in the peripheral blood (3-8% of leukocyte population) in comparison 
to neutrophils they are often not the first cells at the site of inflammation; this, 
combined with differences in adhesion molecule expressions, usually means they are 
preceded by neutrophils
62
. Following a persistent state of inflammation, neutrophils 
become depleted, but by contrast, blood monocytes accumulate and differentiate into 
inflammatory macrophages, which complete phagocytosis and destruction of the 
injurious agents, signalling a resolution of an inflammatory state. However in a more 
chronic state of inflammation neutrophils persist – due to mechanisms including 
impaired apoptosis
60
. Monocytes can release cytokines without differentiating into 
dendritic cells and macrophages and this is important in the initiation of the 
inflammatory response and recruitment of other immune cells. In severe sepsis the 
ability of monocytes to produce cytokines can be down regulated by unknown 
mechanisms
63
. Human leukocyte antigen (HLA) expression is also down regulated in 
monocytes during sepsis and researchers think this plays a crucial role in the 
development of immunodeficiency and subsequent nosocomial infection
64
. 
2.1.4 The role of the macrophage in inflammation  
Macrophages are monocytes that have undergone migration into tissues and have 
become differentiated. The activation of macrophages leads to responses that are 
typical of innate immunity, such as the rapid generation of an inflammatory 
response, and they play a role as efficient effectors for the clearance of 
microorganisms. They can also become specialized, so called “tissue macrophages” 
i.e. in the lung (alveolar macrophages) or liver (Kupffer cells). Macrophages are 
professional phagocytes and play a crucial role in antigen presentation and 
recruitment of the adaptive immune system through their use of Major 
Histocompatibility Complexes (MHC)
65
.  Macrophages, monocytes and endothelial 
cells up regulate their expression of tissue factor during sepsis which leads to a “pro-
coagulant state”66, this can lead to depletion of clotting factors and eventually 
disseminated intravascular coagulation. Macrophages, in comparison to monocytes, 
appear to have a longer period of cytokine production and in vitro 
67
 and in vivo 
64
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studies have shown that various tissue macrophage populations are responsible for 
the production of an array of cytokines. 
2.1.5 Aims of this chapter 
Understanding the role of TLRs, NFκB pathways and individual immune cell 
function has allowed researchers to explore various routes of therapeutic targets in 
order to manage the inflammatory response in those conditions such as sepsis, where 
it becomes somewhat overzealous. However as discussed in the general introduction, 
sometimes these mechanisms are more complex than first perceived and like in the 
case of TNF-α, IL-1 & IL-610, recapitulating an inflammatory response using so 
called “sterile” techniques can provide information that is dissimilar to the true 
condition. The aim of this chapter is not to assess the validity of the sterile 
inflammation model, but use it to examine the relationship between the TLR and 
activation of the “classical” NFκB pathway. By examining this in two separate cell 
lines (murine and human) a comparison can be made between species and help 
understand the contribution of possible differences on the molecular levels can have 
towards the existing translational disconnect between murine and human sepsis. 
Comparing two cell populations can also provide information about the role of two 
separate immune cells in inflammation, their respective sensitivities to LPS and their 
capacity for cytokine production. Bonizzi et al 
19
  identified the P65-P50 heterodimer, 
NFκB protein as the most common protein in the “classical” pathway that 
translocates from the cytoplasm to the nucleus after cellular stimulation with LPS. 
Therefore these experiments will also determine whether or not p65 detection can be 
a reliable indicator of activation of the pathway. The hypothesis is stated below: 
“LPS-induced responses depend on cell type and species: THP1 and RAW 264.7 
cells dosed with LPS will exhibit varying levels of activation of the NFκB pathway 
(via the TLR receptor) and subsequent nuclear translocation of the P65 subunit, 
depending on the concentration of LPS.” 
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Figure 2.1: The Figure is taken from Bonizzi et al
19
 NFκB “alternative” signalling pathway. 
Activation of the pathway results in the translocation of RelB/p100 from the cytoplasm to the 
nucleus. This pathway is suggested to be more primarily concerned with the maintenance of 
secondary lymphoid organs (i.e. the spleen). 
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2.2 Materials and Methods  
2.2.1 Materials 
The two cell lines used in these experiments were THP1 human leukemic monocyte 
and RAW 264.7 murine macrophages. Both were obtained from SIGMA, Aldrich 
(88081201 & 91062702). THP1 cells are an immortalised cell line derived from the 
peripheral blood of a 1-year old male with acute monocytic leukaemia. RAW 264.7 
cells are a murine cell line isolated from ascites of a tumour induced male mouse by 
intraperitoneal injection of Abselon Leukaemia virus (A-MuLV). THP-1 cells were 
cultured in RPMI-1640 (SIGMA, Aldrich R8758) and RAW 264.7 in Dulbecco’s 
modified Eagle media (DMEM, LONZA). LPS used in dosing was obtained by 
phenol extraction from Escherichia coli 0111:B4 (SIGMA, Aldrich L2630). 
Materials used in casting acrylamide gels where obtained from Bio-Rad and included 
ammonium persulfate (APS), tetramethylethylenediamine (TEMED), Protogel 
(Acrylamide), running buffer and stacking buffer. Three antibodies where used in 
western blotting; mouse monoclonal IgG against p65 (Santa cruz biotechnology, Inc. 
sc-109), mouse monoclonal IgG against β-actin (Abcam® mAbcam 8224) and goat 
derived monoclonal anti-mouse IgG (SIGMA, Aldrich A0168).  Chemiluminescence 
reagents were bought as a Proteoqwest™ kit from SIGMA,Aldrich. Densitometric 
analysis was done using visionworks® software and data analysis was done in 
Microsoft excel ® and GraphPad Prism 5 ®. 
2.2.2 Cell culture of THP1 and RAW 264.7 
All cell culture work was carried out in a sterilized cell culture hood using aseptic 
technique. THP1 cells were cultured in RPMI-1640 cell culture media treated with 
10% foetal bovine serum (FBS), L-glutamine and streptomycin. Frozen THP1 cells 
where thawed in a water bath at 37°C and added to 15 mls of media in a 15 ml falcon 
tube. Cells were then centrifuged at 1500 RPM for 5 minutes. Media was poured off 
and the cells were re-suspended in 1ml of media and trypan exclusion was done to 
count cells manually on a haemocytometer (improved Neubauer grid) and assess 
viability (cells were only used if viability was greater than 90%). Cells were then 
seeded 3-8 x 10
5
 per ml of media in a T75 cell culture flask and incubated at 37 °C; 5 
- 7% CO
2
 in an upright position until the cells reached a critical density and enough 
were cultured for the experiment. Cells were then centrifuged and counted as 
described and seeded at 5x10
6
 per ml in 7mls of media within a smaller T25 cell 
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culture flask and incubated overnight before dosing. 8 flasks in total (40x10
6
 cells) 
where required for the experiment; 7 doses and a negative control. Cells were only 
used for experiment during passage 9-11.  
RAW 264.7 cells where cultured in DMEM treated with 10% FBS, L-glutamine and 
streptomycin. Frozen cells were thawed in a 37°C water bath and added to 15 mls of 
media in a 15ml flacon tube and centrifuged at 2000 RPM for 5 minutes. Media was 
poured off and the cells were re-suspended in 1ml of media and trypan exclusion was 
done to count cells manually on a haemocytometer (improved Neubauer grid) and 
assess viability (cells were only used if viability was greater than 90%). Cells were 
then seeded at 20,000 cells per cm
2
 in a T75 flask (1.5 x 10
6
 cells per flask) and 
incubated horizontally at 37 °C; 5 - 7% CO
2
 until cells were 60-80% confluent and 
steps were repeated until enough were cultured for the experiment. As RAW 264.7 
cells are semi-adherent a cell scraper and wash media (DMEM) was used to remove 
adherent cells from the flask. For the experiment cells were seeded at 1x10
6
 cells per 
ml in 5mls in a T25 flask and incubated overnight before dosing. 7 flasks in total 
(35x10
6
 cells) where required for the experiment; 6 doses and a negative control. 
Cells were only used for experiment during passage 15-20. 
2.2.3 Dosing regimen to investigate LPS response on p65 translocation 
After being seeded and allowed to settle for 24 hours, cells were dosed.  
Optimization of the method showed that RAW 264.7 cells required larger doses of 
LPS in order to elicit a detectable level of p65. The doses for each cell line were as 
follows: 
 Dose of LPS ng/ml 
THP-1 Negative 
control 
0.1 0.3 1 3 10 30 100 
RAW 
264.7 
Negative 
control 
3 10 30 100 300 1000 
Table 2.1 table showing the dosing regimen used to dose cell lines in order to 
measure p65 translocation. 
For each experiment a stock solution of LPS was made up and diluted further in 
bijous depending on the desired concentration that was to be achieved. Bijous were 
spun after LPS was added to prevent LPS from sticking to the sides and to ensure 
that the concentration was consistent. After dosing cells were placed into an 
incubator for 1 hour before being transferred to 15ml falcon tubes. 
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2.2.4 Nuclear extraction and protein quantification  
Nuclear extraction was carried out on ice in order to prevent degradation of p65. 
Nuclear extraction buffers were made up as follows: 
BUFFER A BUFFER B BUFFER C 
NaCl NaCl NaCl 
HEPES (pH 8) HEPES (pH 8) HEPES (pH 8) 
Sucrose Glycerol Glycerol 
EDTA EDTA EDTA 
Spermidine Spermidine Spermidine 
Spermine Spermine Spermine 
Triton X-100 dH2O dH2O 
dH2O   
*NaCl – sodium chloride, HEPES- 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid, EDTA-Ethylenediaminetetraacetic acid, dH20- distilled water. 
Table 2.2. Table showing the protocol for making the nuclear extraction buffers for 
nuclear extraction of proteins following dosing with LPS. 
Stock solutions where stored in a fridge at 4
o
C before being aliquoted for each 
extraction. Once aliquoted the buffers were supplemented with 2-mercaptoethanol a 
protease inhibitor cocktail. Once cells had been transferred to a 15ml falcon tube 
they were spun down (at respective RPMS and times used in cell culture, see 2.2.2) 
into a pellet and excess media was poured off. The pellet was then re-suspended in 
4mls of Hank’s balanced salt solution (HBSS). Samples where then centrifuged into 
a pellet and the salt solution was poured off. Pellets where then re-suspended in 
100µl of buffer A in order to rupture the cell membranes and release cytosolic 
contents. After re-suspension samples in buffer A were transferred to freshly labelled 
eppendorf tubes. Samples where then spun at 3500 RPM at 4
o
C for 5 minutes. 
Excess buffer A was poured off and 100µL of wash buffer B was added and the 
pellet re-suspended. The samples where again spun and the excess solution poured 
off. The pellets where then re-suspended in 50µ (RAW 264.7) or 80µl of Buffer C in 
order to rupture the nucleus. Samples where incubated on ice for 30 minutes before 
one final spin and the supernatant aliquoted into eppendorf tubes and stored at -80
o
C 
before being used for experiments.  
Before electrophoresis protein was quantified using the method described by 
Bradford
68
 in order to quantify and standardize the amount of protein loaded from 
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each sample onto the well. Each dosing and nuclear extraction process was carried 
out three times (on different days) on each cell line in order to gain three sets of 
samples and achieve an overall “N” number of 3 for analysis and measure intra-
experimental assay variability. 
2.2.5 Acrylamide gel preparation 
Gels were cast using the gel casting equipment and reagents from Bio-Rad. 7.5% 
acrylamide gels were needed in order to separate the proteins out enough for 
analysis. These gels were made up by altering the protocol provided by Bio-Rad for 
making 10% gels and reducing the volumes of all the reagents and making up to the 
same volume with distilled water. The table demonstrates this below: 
 Running gel 
(7.5%) 
 Stacking 
gel (4%) 
Protogel (Acrylamide) 2.5 Protogel (Acrylamide) 0.7 
Resolving buffer 2.6 Resolving buffer 1.2 
Distilled water 4.9 Distilled water 3.0 
TEMED 10µl TEMED 5µl 
APS 100µl APS 25µl 
Table 2.3 Protocol for preparation of Acrylamide gel 
2.2.6 Running a reducing gel to separate nuclear proteins from extract 
5µg of each sample was aliquoted into a newly labelled eppendorf tubes. Reducing 
agent and sample buffer where mixed together (3:7) in a separate eppendorf and 5µl 
was added to each sample. Samples where then placed on a heat block (85°C) for 5 
minutes. Afterwards samples where incubated on ice for 10 minutes.  Hand-cast gels 
were inserted into the gel holder within the electrophoresis chamber and samples 
were loaded into each of the wells left to right in increasing concentration. Tris 
glycine buffer was poured into the chamber as a cooling blanket. Samples were 
loaded onto the gel from left to right in increasing concentrations using a pipette and 
a protein ladder (Bio-Rad Kaleidoscope) was added onto the  farthest left hand side 
of the gel. The protein ladder allows the molecular weight of the protein to be 
estimated and identification of the desired protein (i.e. p65 & Actin). 90V was 
applied for 10 minutes and then increased to 150V for 45 minutes. 
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2.2.7 Immunoblotting for p65 subunit of NFκB 
The gel was carefully removed and then sandwiched between pre-soaked 
nitrocellulose membrane and filter paper and inserted into a transfer chamber. The 
transfer chamber was filled with 1x transfer buffer (100ml 10x buffer consisting of 
glycine and Tris base, 200ml methanol and 700ml of distilled water).  A current of 
80V was supplied for 1 hour. Sufficient transfer was detected using ponceau red 
stain. Membranes where then washed four times for 5 minutes with 0.1%/1x Tween, 
Tris & buffered saline (TTBS) while being agitated. Afterwards they were placed 
into 10% analytical grade non-fat milk (Bio-Rad) for 45 minutes while being 
agitated. Membranes where then cut at the 50kDa marker (using the Bio-Rad 
Kaleidoscope ladder)  with a scalpel in order to incubate each section with the 
appropriate antibody. As p65 has a molecular weight 65KDa the >50kDa section was 
incubated primarily with mouse monoclonal anti-p65 antibody made up in 2% milk 
to a concentration of 1:1000; while the lower section was incubated primarily with 
mouse monoclonal anti-β actin made up to a dilution of 1:160000 in 2% milk. Both 
were incubated for 1 hour while constantly being agitated. Membranes were then 
washed 4 times for 5 minutes with 0.1%/1x TTBS. Both membranes were then 
incubated with the secondary antibody (goat derived mouse monoclonal) against 
IgG. The p65 membrane was incubated at a concentration of 1:5000 made up in 2% 
milk while the β-actin membrane is exposed to a secondary antibody dilution of 
1:10000. 
The secondary antibody was linked to horseradish peroxidise with the ability to 
cleave chemiluminescent reagents generating a detectable signal. 
2.2.8 Chemiluminescence and Development of actin and p65 
Proteoqwest™ reagents were mixed up in a bijou. Excess reagents were washed off. 
Membranes were then fixed to a development cassette and developed onto an X- ray 
film in a dark room. Exposure times where optimised until an acceptable signal 
strength and film quality was obtained for densitometry. Films where then soaked in 
fixing and developing solutions while in the dark room. 
2.2.9 Densitometry and interpretation of p65:actin ratios 
Films were scanned onto a computer and using subtraction analysis on 
visionworks®, values for densities of p65 and actin bands were calculated. This 
 
 47 
allowed a p65:actin ratio to be calculated were increases in density of p65 
corresponded with increasing values. Data was interpreted on Microsoft excel ® and 
curves constructed using GraphPad Prism 5 ®. 
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2.3 Results  
2.3.1 Detection of p65 nuclear translocation in THP1 cells dosed with LPS  
The nuclear extract of the THP1 cells dosed with LPS was collected after 1 hour to 
quantify (with densitometry) the translocation of p65 from the cytoplasm to the 
nucleus after stimulation of the cells with LPS. It was found that increasing the 
concentrations of LPS stimulated translocation of p65 from the cytoplasm to the 
nucleus in a dose-response relationship. An increase in basal p65 density (Mean 
0.214 SD 0.0238) was seen at doses as small as 0.1ng/ml (Mean 0.519 SD 0.0641). 
This indicates that p65 is a reliable marker of TLR activation and subsequent down –
stream signalling leading to NFκB “classical” pathway activation. Furthermore 
activation of this pathway after 1 hour of cellular exposure to LPS demonstrates the 
acute nature of potential cytokine production and response to low doses reflects the 
sensitive nature of these human monocytes to insult. Figure 2.2 displays the 
densitometry results of each replicate of the experiment. Figure 2.3 displays the 
means of the replicates. The trend is clear; it shows there is a gradual increase in the 
p65: Actin ratio with increasing dose of LPS, indicating an increase in the nuclear 
p65. There was a significant difference between all doses and controls (p<0.05). This 
similar trend was also seen between individual doses. 
Coefficient of variation is defined as the standard deviation of a set of data divided 
by the mean. Here it was used to assess inter experimental variation. The overall 
range of variation was 11.5-27.62%. This shows that there is a high level of inter-
experimental variability between day to day assays. Figure 2.4 shows this 
graphically. 
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Figure 2.2: Results of densitometry on developed films of Immunoblots of THP1 
nuclear extract from cells dosed with varying concentrations of LPS. All bar charts 
are displayed with P65:Actin ratio on the Y axis and LPS dose (ng/ml) on the X axis. 
Underneath are pictures of p65 1 minute films on top along with 10 second actin 
films on the bottom. A-C are repeats of the same method done on three sets of 
different nuclear extracts carried out on dosing experiments done on different days 
(N=3). Immunoblots were carried out on the same day. 
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Figure 2.3: Results of densitometry on developed films of Immunoblots of THP1 
nuclear extract from cells dosed with carrying concentrations of LPS. Bar charts are 
displayed with P65: Actin ratio mean (N=3)  on the Y axis and LPS dose (ng/ml) on 
the X axis. Means are plotted with standard error of the means (SEM).  
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Figure 2.4: Results of densitometry on developed films of Immunoblots of THP1 
nuclear extract from cells dosed with carrying concentrations of LPS.(A) is a 
combination of all the replicates (N=3 in Blue, Red & Green) with P65:Actin ratio 
on the Y axis and LPS dose (ng/ml) on the X axis. The bar chart shows the variability 
between each set of results and (B) shows the % coefficient of variation (X axis) 
between each replicate dose. This was done by dividing the standard deviation by the 
mean. The range of variation was 11.5-27.62%. 
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2.3.2 Detection of p65 nuclear translocation in RAW 264.7 cells dosed with LPS  
The nuclear extract of the RAW 264.7 cells dosed with LPS was collected after 1 
hour to quantify (with densitometry) the translocation of p65 from the cytoplasm to 
the nucleus after stimulation of the cells with LPS. It was found that increasing the 
concentrations of LPS stimulated translocation of p65 from the cytoplasm to the 
nucleus. An increase in basal p65 density (Mean 0.17 SD 0.025) was only seen when 
a dose of 3ng/ml (Mean 0.387 SD 0.078) was used (which is much higher in 
comparison to 0.1ng/ml used for THP1 cells) this indicates again that p65 is a 
reliable marker of TLR activation and subsequent down-stream signalling leading to 
NFκB “classical” pathway activation. However in this particular cell line much 
higher concentrations of LPS were required in order to stimulate the cells and a 
maximal response was seen between 100-300 ng/ml (Mean 0.647, SD 0.046 and 
Mean 0.7, SD 0.11 respectively). Higher LPS concentrations lead to a mean decrease 
in mean nuclear p65 density, probably indicating that these higher doses are 
potentially cytotoxic. Figure 2.5 displays the densitometry results of each replicate of 
the experiment. Figure 2.6 displays the means of the replicates. The trend is clear, it 
shows there is a gradual increase in the p65: Actin ratio with increasing dose of LPS, 
indicating an increase in the nuclear p65. There was a significant difference between 
all doses and controls (p<0.05). This similar trend was also seen between individual 
doses. 
Coefficient of variation is defined as the standard deviation of a set of data divided 
by the mean. Here it was used to assess inter experimental variation. The overall 
range of variation was 7-28.7%. This shows that there is a high level of inter-
experimental variability between day to day assays. Figure 2.7 shows this 
graphically. 
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Figure 2.5: Results of densitometry on developed films of Immunoblots of RAW 264.7 
nuclear extract from cells dosed with varying concentrations of LPS. All bar charts 
are displayed with P65:Actin ratio on the Y axis and LPS dose (ng/ml) on the X axis. 
Underneath are pictures of p65 1 minute films on top along with 10 second actin 
films on the bottom. A-C are repeats of the same method done on three sets of 
different nuclear extracts carried out on dosing experiments done on different days 
(N=3). Immuno blots were carried out on the same day. 
 
 
 
 
 
 
(C) 
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Figure 2.6: Results of densitometry on developed films of Immunoblots of RAW 264.7 
nuclear extract from cells dosed with carrying concentrations of LPS. Bar charts are 
displayed with P65: Actin ratio mean (N=3) on the Y axis and LPS dose (ng/ml) on 
the X axis. Means are plotted with SEM.  
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Figure 2.7: Results of densitometry on developed films of Immunoblots of RAW 264.7 
nuclear extract from cells dosed with varying concentrations of LPS.(A) is a 
combination of all the replicates (N=3 in Blue, Red & Green) with P65:Actin ratio 
on the Y axis and LPS dose (ng/ml) on the X axis. The bar chart shows the variability 
between each set of results and (B) shows the % coefficient of variation (X axis) 
between each replicate dose. This was done by dividing the standard deviation by the 
mean. The range of variation was 7-28.7%. 
 
 
 
(A) 
(B) 
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2.3.3 Comparison of p65 nuclear translocation in THP1 and RAW 264.7 cells 
dosed with LPS  
THP1 monocytes did not only respond to lower doses such as 0.1ng/ml, they also 
showed a greater increase in nuclear p65. Similar numbers of cells where used in 
each experiment 5x10
6
 in 7 mls of THP1 cells and 5x10
6
 in 5mls of RAW 264.7 
cells). This could either mean that the individual monocyte cell type is more sensitive 
to LPS than the macrophage or there is a species variation (murine versus human) 
between sensitivities to LPS. Figure 2.8 demonstrates graphically the visible 
differences in response to similar doses of LPS in the two cell lines. This effect could 
also be explained by the nature of the cell culture. THP1 cells are suspension cells 
cell meaning they multiply while suspended in the media, whereas the RAW 264.7 
cells are semi adherent meaning they can adhere to the side of cell culture flasks and 
multiply. This adherence could potentially reduce the available surface area that the 
RAW 264.7 macrophage exposes be stimulated by LPS and subsequent activation of 
the inflammatory pathway.  
 
 
 
 
Figure 2.8: Results of densitometry on developed films of Immunoblots of THP1 
(Red) and RAW 264.7 (Blue). Comparison of similar doses in the two cell lines 
shows higher responses in the THP-1 cell line versus RAW 264.7 at respective doses. 
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2.3.4 Dose-Response relationship and Comparison of p65 nuclear translocation 
in THP1 and RAW 264.7 cells dosed with LPS  
Dose-response relationship describes the change in effects to an organism that a 
varying level of a stressor makes, defined within a certain period of time 
69
. In this 
case the organisms are the cell lines; THP1 and RAW 254.7 and the stressor is LPS. 
Analysis of fold increase in nuclear p65 from basal levels allows for an observation 
of the threshold and range of LPS that the cell lines can respond to and also identifies 
the relationship and relative sensitivities of the cells to changes in dose.  Figure 2.9 
(A) is the dose response curve for fold increase in p65: Actin density against dose 
and (B) is the same but for the RAW 264.7 cell line. Fold increase was calculated by 
dividing the basal level of p65 into all the p65 response seen at each dose. The X axis 
is calculated by log [LPS]; the doses where first converted into pg/ml in order to 
allow for even spacing on the graph. GraphPad Prism 5 ® was used to calculate the 
curves and this software uses the four parameter logistic non-linear regression model 
for curve fitting.  
Comparison of the curves suggest that THP1 cells respond to lower doses of LPS 
than RAW 264.7 cells and  lower doses produce a greater fold increase in the nuclear 
p65 density indicating that they are more sensitive to lower concentrations cells. The 
Hill slope for RAW 264.7 cells was 1.5 whereas for THP1 cells it was between 0.7, 
this suggest that although higher concentration of LPS were required in order to 
cause an effect in the RAW 264.7 cells, the effect was greater and more potent than 
that seen in the THP1 cell line. RAW 264.7 cells appear to be more sensitive to 
changes in concentration of LPS but overall THP1 cells have a higher p65 fold 
increase compared to RAW 264.7 cells. 
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Figure 2.9: Dose-response curves for (A) THP1 and (B) RAW 254.7 cell lines dosed 
with varying concentrations of LPS. X axis are the log values of the concentrations 
with fold increase in the p65: Actin ratio on the Y axis. Fold increase was calculated 
by dividing the mean basal p65 response into all other mean doses. Means are 
plotted with SEM.   
 
 
 
 
 
 
 61 
2.4 Discussion 
NFκB translocation is an important event in the inflammatory response for 
transcription and production of new cytokines including TNF-α, which is not stored 
in the cell but made de novo. In these experiments, p65 detection through 
immunoblotting was demonstrated to be a valuable, reliable way of detecting 
activation of the NFκB pathway in cells dosed with LPS. Gradual dosing showed that 
increasing the dose of LPS resulted in a greater translocation of the p65 subunit of 
NFκB from the cytoplasm to the nucleus of the cell, in both human and murine cells. 
However it appeared that the murine cells required a higher dose of LPS than human 
cells and therefore demonstrated resilience to endotoxin.  
2.4.1 Species variation in response to LPS 
The different dose-response to LPS in human and murine cells has been reported 
before; with RAW 264.7 cells requiring higher doses of LPS in order to elicit similar 
responses to those seen in THP1 cells
70
. TLR 4 is an important receptor expressed on 
most myeloid cell derivatives, that allow them to detect and respond to LPS 
71
. In 
vitro studies have shown that human macrophages up-regulate and increase their 
activation of TLR 4 on stimulation with LPS
72
, whereas murine cells appear to 
down-regulate TLR 4 transcripts under similar conditions 
73
.  This fundamental 
variation in expression pattern could explain the higher levels of p65 translocation in 
human but not murine cells seen in this chapter, as TLR 4 activation is the important 
first step in the phosphorylation of IκB and subsequent release of the p65-p50 NFκB 
heterodimer as part of the classical pathway (see figure 1.1). 
Lymphocyte antigen 6 (or MD-2) an extracellular protein and ligand of the TLR 4 is 
important in LPS binding to this receptor r
74
. Hajjar et al 
70
 demonstrated that the 
human TLR4-MD-2 complex is more sensitive in humans than in mice and has the 
ability to recognize acetylation of the LPS molecule allowing it to generate a more 
specific inflammatory response. Bacteria can undergo acetylation of their LPS in the 
cell wall in response to environmental change. Pseudomonas aeurginosa is a prime 
example in cystic fibrosis patients where it can modify its LPS structure within the 
airway in order to avoid being killed by the innate immune system
75
. On challenging 
THP-1 cells and RAW 264.7 cells with this acetylated LPS and normal (less 
acetylated) E coli LPS, Hajjar et al 
70
 showed that murine cells produced a similar 
response with both types of LPS but human cells were able to differentiate and alter 
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their immune response producing higher levels of NFκB activation and cytokine 
release in response to E coli compared to the more acetylated LPS.  This show that 
even at molecular level humans can modulate their innate immune system in 
response to pathogens in a more specific way than rodents.  
Warren et al 
76
 suggested that the differences in resilience to LPS between species, 
with humans towards one end and rodents towards the other end of a spectrum, may 
not be due to an intrinsic cellular process, but rather may be related to mechanisms 
involving and perhaps regulated by serum proteins. This was demonstrated by the 
ability of isolated mouse serum to suppress the LPS induced TNF-α production in 
macrophages to a greater extent than human serum.  
2.4.2 Immune cell response to LPS 
Upon differentiation to macrophages monocytes lose their ability to multiply and 
their immune functions and their antibacterial properties become enhanced.  The 
monocyte cell itself has been shown to be less sensitive to LPS than the macrophage 
in vivo 
77
 and this was shown by accumulation of NFκB in the cytoplasm of 
differentiated THP1 cells in comparison to non-differentiated cells. Takashiba et al
77
 
concluded that this accumulation was a priming event in making the macrophage 
more sensitive to LPS stimulation and resulted in a more rapid NFκB translocation 
and overall higher nuclear content. Therefore you would have expected to see higher 
levels of p65 translocation in a primed highly sensitive macrophage compared to a 
monocyte. The results within this chapter demonstrated less nuclear translocation of 
p65 in the murine macrophage in comparison to the human monocyte, but these 
results can be explained by the overpowering resilience and species variation
70, 76
 to 
LPS.  
2.4.3 Translational implications  
The results from this chapter demonstrate that immunoblotting p65 is a reliable, 
detectable and reproducible way of measuring activation of the “classical” NFκB 
pathway in murine and human cell lines dosed with LPS. It also demonstrated the 
dose-response relationship of NFκB pathway activation with LPS; where increasing 
doses of LPS resulted in a higher accumulation of p65 in the nucleus of the cells.  
Furthermore, comparison of the human and murine cell lines allowed the significant, 
fundamental molecular differences between the initiating steps in an inflammatory 
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process to be demonstrated. These results, in line with the literature
60, 66
 highlight the 
pitfalls in using murine cell lines, which have been shown to have more primitive 
responses
60
, compared to human alternatives in the study of inflammation. This can 
also be seen on an in vivo level with most wild type mice being highly resilient to 
LPS challenge. The dose of LPS used in most in vivo studies, 1–25 mg/kg, has a 
significant mortality rate 
78
. This dose is much greater than the 2–4 ng/kg dose of 
LPS needed to elicit a similar response of cytokines in humans
79
. Therefore the so 
called “translational disconnect” that exists between in vivo and human sepsis 
appears to begin at a molecular level and is further augmented by the use of stimuli 
that do not efficiently recapitulate the environment of human sepsis in vivo. 
Additionally while immortalized cell lines often originate from a well-known, 
described tissue type, frequently they have undergone mutations to become 
immortal. This will alter the internal physiology of the cell and needs to be taken into 
consideration when analysing results and translating to clinical medicine.  
2.4.4 limitations & future work 
One hour was chosen as a time point as activation of the p65 pathway is known to 
take a short time
80
. A major limitation of this study was that it only looked at a single 
time point. In future work it is hoped to look at a time course in order to ascertain 
whether or not high doses reflect the maximum activation of the pathway. Also 
further analysis is needed in order to investigate how the activation of the pathway 
translates to cytokine production. 
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Chapter 3: 
Comparative histopathological 
analysis of two murine models of 
sepsis 
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3. Comparative histopathological analysis of two murine 
models of sepsis 
3.1 Introduction  
Doi et al
81
  stated in their review on animal models of sepsis that murine sepsis 
should mimic the pace and severity of human sepsis; reproduce key haemodynamic 
and immunologic stages and mimic histology findings in the key organs lung, liver, 
spleen, kidney. Failure of models to do this has led to a reduction in preclinical 
efficacy of therapeutic treatments and a failure of translation. This is most notable in 
the case of the development of monoclonal antibodies against TNF-α, which 
improved survival in endotoxaemic mice, but failed to have a similar translational 
effect in humans
9
. 
3.1.1 LPS model of endotoxaemia  
Endotoxaemia is defined as the presence of endotoxin in the blood. LPS a bacterial 
endotoxin from Gram negative bacteria is a widely used in models of murine sepsis 
and endotoxaemia by inducing “sterile inflammation”. In experimental  animals, a 
bolus injection of LPS will induce a sharp, but transient increase in pro-inflammatory 
cytokines such as TNF-α, IL-1, and IL-68, whereas in human sepsis the host response 
is triggered by live bacteria, giving detectable cytokine levels that are significantly 
lower, but sustained over a longer period of time. Despite the disparities LPS is 
widely used in research because models are relatively straightforward, produce the 
greatest homogeneity among all in vivo models of sepsis and are, thus, relatively easy 
to replicate
82
.  
LPS has become widely superseded by the development of surgical techniques for 
the induction of peritonitis. The two most common procedures used now are CLP 
and CASP. These methods produce a so called “polymicrobial” sepsis and not a 
“sterile inflammation”. Remick et al8, 47 found that although the mortality and the 
morbidity of the two models (LPS versus CLP) was similar, the inflammatory 
responses evoked are distinctly different
47
.  In their study LPS induced substantially 
higher levels of cytokines than CLP and these peaked around 8 hours and then began 
to decline, cytokine levels in the CLP model were continuing to increase at the 8 
hour time point and often exceeded the LPS induced values at this time. Remick et 
al
83, 84
 therefore demonstrated that CLP was more successful in recapitulating this 
gradual increase in cytokines similar to human sepsis; however, Maeir et al
46
 found 
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that CASP was a superior model to CLP, as mice undergoing CLP often developed 
intra-abdominal abscesses which changed the focus of their peritonitis and sepsis
46
.   
Although most research has been aimed at highlighting the difference between 
cytokine levels in each model, not a lot of research has gone into the significance of 
these cytokine levels with regards to organ damage and organ damage during sepsis, 
seeing whether or not it is similar to the human disease. Often, damage during sepsis 
is not from primary bacterial particles or LPS, but due to an over active immune 
response and production of cytokines
62
. 
3.1.2 Faecal peritonitis model of sepsis  
The major problems with both these models along with those highlighted in section 
(see 1.3) appear to be reproducibility and variability. It was often hard to control the 
size of the ligations and punctures and severity would differ from experiment to 
experiment. Gonnert et al
48
 seemed to overcome this with a more robust 
polymicrobial model using a standardised polymicrobial inoculation model. They 
produced a batch of stool that was able to reproduce a clinically significant, 
quantifiable and reproducible model of sepsis in rodents. The stool was inoculated 
into the peritoneum of mice and induced a cytokine response similar to that of human 
sepsis (reflected by the rises and kinetics of IL-6 and IL-10). Microbiological 
analysis showed that the stool contained Escherichia coli (E coli) and Bacteroides 
species (Bacteroides spp), important Gram negative organisms that are known 
causatives of sepsis in humans
85
. The stool preparation was stored at -80ᵒC and over 
time (3 years) the bacterial content of the stool remained consistent. The 
translatability of the model was also tested by the administration of antibiotics and 
fluid resuscitation, these are common treatments in human sepsis and administration 
of antibiotics had similar effects on survival as did the fluid recovery mimicking 
effectively the responses that would be achieved in ICU patients. Follow up of the 
mice two weeks after also gave researchers the opportunity to study the chronic 
inflammatory changes, in particular the liver, which still contained marked levels of 
activated immune cells.   
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3.1.3 Pathology of organ damage in sepsis 
Organ dysfunction is a common complication in human and experimental sepsis. 
These dysfunctions are attributed to the huge increase in systemic cytokine and 
mediator release which results in immune dysregulation, hormonal alterations, 
metabolic changes, mitochondrial dysfunction, micro- vascular dysfunction, 
epithelial dysfunction and coagulation activation
58
 (see 1.3). However, in sepsis 
models, organ dysfunction varies depending on the type of insult and model used.  
Dear et al
86
 demonstrated that acute renal failure (ARF) and liver dysfunction 
induced by polymicrobial sepsis through CLP had significant pathophysiological 
differences to ARF and liver dysfunction induced by administration of LPS. LPS is 
dependent on TLR 4 activation for de novo production and release of TNF-α, 
However, Dear et al
86
 showed that polymicrobial CLP has the potential to activate 
multiple different receptors and is not dependent on TLR 4. Subsequent rises in 
TNF-α seen with LPS treatment lead to renal cell apoptosis and as CLP mice showed 
lower levels of serum TNF-α, they showed an absence of renal cell apoptosis. The 
conclusion was that polymicrobial sepsis induced by CLP more accurately reflects 
human sepsis than administration of LPS. In humans and polymicrobial sepsis, 
severity is not dependent on TLR 4
87
, this could be a significant contributing factor 
for reduced efficacy of therapies based on TNF-α inhibition.  Post-mortem analysis 
has also shown that despite a large renal dysfunction in septic patients, often no 
apoptosis is detected in routine haematoxylin and eosin (H&E) staining sections
88
. 
Although apoptosis is not the mechanism for renal dysfunction in the CLP model, 
significant levels have been noted in the liver and spleen during human and LPS 
induced experimental sepsis
88, 89
. Apoptosis in the spleen is reported to be significant 
in sepsis mortality and can occur via TNF-α independent pathways86. The 
discrepancies between mode of cell death and cellular level organ dysfunction, 
highlight the need for an in depth histopathological analysis of individual tissues 
from the LPS model and comparison with the newer more clinically relevant faecal 
inoculation model, to see which are consistent with changes observed in human 
tissue. 
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3.1.4 Liver damage during sepsis  
In patients with sepsis and SIRS, the liver plays a significant role as a source of 
inflammatory mediators. The liver is pivotal in modulating the systemic response to 
severe infection, because it contains the highest portion of macrophages (Kupffer 
cells) in the body; these Kupffer cells can effectively clear the endotoxin and bacteria 
that initiate the systemic inflammatory response. However, in sepsis, the over-
zealous inflammatory response often becomes counter-intuitive as the liver itself 
begins to become damaged. In experimental modelling, LPS causes a significant 
increase in TNF-α which induce secondary hepatocyte apoptosis and has no primary 
hepatotoxic effect
90
.  
Detailed liver studies by Koskinas et al 
91
 in patients with sepsis showed that the 
main histological changes were hepatitis and steatosis in the majority of patients 
dying from sepsis. Liver biopsies showed portal inflammatory infiltration in 73.3%, 
centrilobular heaptocyte necrosis in 80%, lobular inflammation in 66.7% and 
hepatocellular apoptosis in 66.6% of patients. This apoptotic/necrotic pattern in the 
liver has also been observed in a further histopathological analysis of a similar group 
of patients
88
. In experimental models, Gonnert et al
48
 reported leukocyte–
endothelium interactions (i.e. leukocyte rolling and adhesion) within the liver 15 
hours after the septic insult. Interestingly, they did not report any apoptosis or 
necrosis at this time, although they reported undetectable levels of TNF-α at 5 hours, 
concluding that levels must have normalized before serum was taken off for 
detection
48
. Follow up of the mice showed a pattern of persistent immune cell 
infiltration (i.e. neutrophils, prominent macrophages and irregularly shaped 
lymphocytes) and altered architecture. In experimental modelling, TNF-α induced 
hepatocyte apoptosis is an early, general, and possibly causal event during 
experimental liver failure triggered by inflammatory stimuli such as LPS
92
. 
Understanding acute changes in the liver may provide information on the 
discrepancies between models and show whether or not at cellular level, LPS or 
faecal inoculation involves changes similar to human sepsis. 
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3.1.5 Adipose tissue and sepsis  
Adipose tissue has become regarded as a significantly active endocrine organ that 
has the potential to play a major role in the inflammatory process through expression 
of a diverse set of receptors, proteins, hormones and the secretion of a large family of 
proteins called adipokines
93
. In humans, adipose tissue is situated in the sub-cutis 
beneath the skin and around organs as visceral fat. Adiponectin is a protein 
exclusively secreted from adipose tissue that modulates a number of metabolic 
processes, including glucose regulation and fatty acid catabolism
94
. Plasma 
adiponectin declines before the onset of obesity and insulin resistance in non-human 
primates, suggesting that hypoadiponaectinemia contributes to the pathogenesis of 
these conditions and the so called “metabolic syndrome”95.  Levels of the hormone 
are inversely correlated with body fat percentage in adults
96
. 
Three receptors for adiponectin exist but the most abundant are AdipoR1 & R2. The 
activation of AdipoR1 & R2 results in increased hepatic and skeletal muscle fatty 
acid oxidation, increased skeletal muscle lactate production, reduced hepatic 
gluconeogenesis, increased cellular glucose uptake and inhibition of inflammation 
and oxidative stress. Several studies have highlighted the ability of adiponectin to 
modulate the inflammatory response. In vitro adiponectin decreases the production of 
TNF-α and IL-6 in LPS stimulated human macrophages97. In rats with induced 
polymicrobial sepsis through CLP, plasma adiponectin levels negatively correlated 
with plasma LPS and TNF-α levels 98. Teoh et al99 concluded that adiponectin 
homeostasis serves to limit leukocyte infiltration, chemotaxis, and endothelial 
activation. Furthermore, adiponectin deficiency has been shown to exacerbate 
hepatic injury during CLP and this is hypothesised to be a result of inhibition of 
TNF-α release (demonstrated in obese KK-Ay mice)100. The pathological 
implications indicate that adiponectin deficiency leads to enhanced hepatic 
steatosis
101
, a known mechanism for hepatic injury in sepsis
89
.   
Adipose tissue recruitment and activation is, therefore, an important stage in human 
sepsis as adiponectin has been shown to play a significant role in modulating the 
inflammatory process
97, 98, 100-102
.  By analysing adipose tissues and a diverse set of 
organs in various mice models of sepsis, a difference in endothelial activation and 
leukocyte recruitment into tissues might help elicit further, which models are 
mimicking the septic process in humans most effectively. 
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3.1.6 Skeletal muscle and sepsis  
Maintenance of skeletal muscle function is important in sepsis in order to effectively 
ventilate and maintain respiratory capacity. Studies have shown that the proteolytic 
activity of the proteasome is higher in skeletal muscle from patients with sepsis and 
multiple organ failure compared with healthy controls and that both respiratory and 
leg muscles are affected similarly
98
. This mechanism has been attributed to increased 
transcription of the ubiquitin-proteasome pathway proteins
83
.  
Skeletal muscle has also been shown to be an important site of adiponectin activity 
during sepsis.  Delaigle et al
84
 found that adiponectin is up-regulated in vivo and in 
vitro in human and rodent myotubes in response to inflammatory stimuli, concluding 
that it’s over expression may be a local anti-inflammatory protection and a way to 
supply extra energy during inflammation. This was further reinforced by Wei et al
103
 
who found that induction of adiponectin into skeletal muscle in response to an 
inflammatory infiltration appears to be a crucial mechanism to counteract excessive 
inflammatory damage, oxidative stress, and subsequent apoptosis. These mechanisms 
highlight the protective role of adiponectin in the maintenance of muscle function 
and inadvertently respiration.  
The subtle inflammatory infiltrations and recruitment of leukocytes appears to be 
significant in human sepsis and should be equally important in experimental sepsis, 
along with trying to mimic the criteria stated by Doi et al
81
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3.1.7 Aims of this chapter  
Recreating an effective model of experimental sepsis similar to that of humans is 
proving difficult. However, more recent models are moving closer to mimicking key 
immunological, endothelial and cytokine alterations along with levels of organ 
dysfunctions. These models are superseding and replacing the LPS model of 
endotoxaemia favouring a “polymicrobial” approach instead. Analysis of cytokines 
has already shown that a bolus of LPS will induce a sharp non sustained rise in key 
cytokines, whereas newer surgical models favour a more sustained gradual incline 
57
. 
The aim of the experiments of this chapter is to investigate how these cytokine 
differences will correspond with acute changes, and inflammatory infiltration of 
organs (in particular the liver). This will be carried out by looking at how the LPS 
model differs from the newer faecal peritoneal inoculation model proposed by 
Gonnert et al
48
. At the same time it will allow for analysis of differences in 
recruitment of other tissue namely fat and skeletal muscle which have shown to be 
key players in human inflammation and sepsis
104, 105
. Detailed histopathological 
analysis of the LPS model will also allow for discrepancies and “endotoxaemia” 
phenomenon to be highlighted that may not be representative of normal human 
sepsis. APAP will also be included as positive control at a dose where organ damage 
will be expected. This will also provide information about how mechanisms of organ 
damage in drug toxicity differ from those with inflammation. 6 hours was chosen as 
a time point for culling as it allowed enough time for serum cytokine levels to elevate 
high enough so acute , early, changes in tissue can be observed. This will also allow 
for a direct comparison with tissue from the same time point provided by our 
collaborators. The hypothesis is restated below: 
“LPS induces histopathological changes different from faecal inoculation: 
Histopathological analysis of tissues from mice dosed IP with LPS or faecal 
suspension will show differing levels of tissue recruitment and damage of various 
tissues compared to controls and those dosed with acetaminophen.” 
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3.2 Materials and Methods  
3.2.1 Materials 
Tissue from the faecal peritonitis murine model of sepsis was kindly donated by Jana 
Lemm, Department of Anesthesiology and Intensive Care Research Unit: Molecular 
Mechanisms of Organ Failure Research Center, Lobeda Erlanger Allee 101, 
Friedrich-Schiller-University, D-07747 Jena, Germany. Samples were collected from 
C57/BL6 mice at necropsy and included liver, gastrocnemius muscle, epididymal, 
peri-renal and sub-cutaneous fat. Samples were fixed in 4% paraformaldehyde (PFA) 
and embedded in paraffin cassettes before being shipped to the UK. Mice used in the 
LPS dosing experiment were 23 male C57BL/6 mice (25-30g) obtained from 
Charles-River (Margate, UK). LPS used in dosing was obtained by phenol extraction 
from Escherichia coli 0111:B4 (SIGMA, Aldrich L2630). Acetaminophen and 
sodium chloride for saline (SIGMA, Aldrich A7085, S7653) along with LPS where 
all in powder form and were reconstituted in distilled water before administration.  
3.2.3 Intra-peritoneal inoculation of faeces into C57/BL/6 mice  
11 male C57BL/6 mice (25-30g) received an intraperitoneal injection (right upper 
quadrant) for induction of sepsis, 1.75 mL/kg body weight stool suspension, diluted 
(1:4) in saline, was injected i.p. into the right lower quadrant of the abdomen with a 
21-gauge cannula as described by Gonnert et al
48
. 11 control animals were injected 
in a similar manner with normal saline. All animals also received 25 µl per gram 
body weight normal saline subcutaneously to compensate for fluid losses. Mice were 
then euthanized at 6 hours using carbon dioxide suffocation and a standard protocol 
for removal of organs was followed. Samples from the liver, epididymal, peri-renal 
and sub-cutaneous fat depots along with muscle gastrocnemius were either frozen or 
fixed in 4% paraformaldahyde (PFA) before being embedded in paraffin cassettes. 
Frozen samples where then transported securely to the UK on dry ice. Fixed samples 
were shipped at room temperature.   
3.2.2 Animal housing and preparation 
23 male C57/BL/6 (25-30g) were ordered from the biomedical services unit and 
allowed to acclimatize for one week prior to the experiment. Animals were treated in 
accordance with guidelines set out by the home office (project licence 40/3143) with 
regards to the handling and experimentation of animals. Throughout the experiment 
animals had free access to food and water and were kept in cages. 
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3.2.3 Dosing regimen of C57/BL6 mice with LPS, APAP & saline  
Animals were weighed, marked and divided into three groups and given one of the 
following treatments intra-peritoneally (right upper quadrant): 25mg/Kg LPS (a dose 
known to induce lethal endotoxaemia), Saline (an equivalent amount to that used in 
LPS dosing) or 350mg/Kg of acetyl-para-aminophenol (APAP) and culled using 
carbon dioxide suffocation at 6 hours (allowing results to be comparable with our 
collaborators experiments). Animals were dosed based on weight and the schedule is 
summarised in the table below: 
Animal 
numbers 
Total 
number 
Intervention  Dose Dose based 
on average 
weight of 30g 
Cull 
1-11 11 LPS 25mg/Kg 0.75mg 6 hours 
12-17 6 No 
intervention  
No 
intervention  
No 
intervention 
6 hours 
18-23 6 acetaminophen 350mg/Kg 10.5mg 6 hours 
Table 3.1: Table showing the dosing regimen and number of animals in each group 
APAP dosed mice were included as a positive control to ensure that dosing was done 
correctly, but also to compare if necrosis and apoptosis patterns along with organ 
damage differs to that caused by inflammation. All animals were given sub-
cutaneous saline to compensate for fluid volume of 25 µl per gram body weight. 
3.2.4 Culling and sample collection  
Animals were euthanized by carbon dioxide at 6 hours. Blood was removed and spun 
to isolate the serum (which was frozen at -80°C). Tissue samples removed included 
the liver, epididymal, peri-nephritic and sub-cutaneous fat (small deposits from the 
back) along with muscle gastrocnemius (similar to the samples sent from our 
collaborators). Heart, lungs, spleen, thymus, bone marrow, brain & intrascapular 
brown adipose tissue were also removed for an in-depth analysis of LPS changes at 
the cellular level. Aliquots of the organs were frozen and stored at -80°C, while 
microscopic samples were treated as described below. 
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3.2.5 Tissue fixation, slide preparation and interpretation  
Tissue was fixed in 4% PFA  before being cut into an appropriate size and placed in 
a cassette and tissue processor overnight to remove water and replace it with paraffin 
wax. Within the processor tissues are dehydrated using increasing concentrations of 
ethanol and excess ethanol was removed using xylene. Finally molten paraffin wax 
replaces the xylene and the tissue is embedded into moulds before sectioning. Basic 
staining (Haematoxylin & eosin) was carried out for a general histopathological 
assessment of the tissue. Periodic acid-schiff (PAS) was also done where appropriate. 
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2.3 Results  
A detailed description of the histopathological findings of all organs/tissues from 
each animal is provided in Appendix 1. Animals are indexed by their case number 
and this is given along with the study number, intervention and a description of the 
major histological findings from each individual tissue. 
2.3.1 Histological findings in the liver  
Livers from control animals did not exhibit any histological abnormalities. There was 
presence of diffuse hepatocellular glycogen accumulation, represented by a diffuse 
cloudy cytoplasmic vacuolation in HE stained sections (figure 3.1) and the presence 
of granular Periodic acid Schiff (PAS)-positive material after the PAS reaction (data 
not shown). 
 
 
 
Figure 3.1. C57Bl6 mouse at 6 hours post intraperitoneal inoculation of saline 
(control animal; case No 12L-1405). Liver. No histological abnormality is 
recognised. Hepatocytes exhibited diffuse cloudy cytoplasmic vacuolation, consistent 
with glycogen accumulation. PV: portal vein. HE stain. 
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Animals that had been intraperitoneally inoculated with faecal suspension exhibited 
an acute suppurative perihepatitis, represented by a variably thick layer of 
neutrophils attached to the liver surface. These were mixed with amorphous granular 
eosinophilic material (faecal matter) and occasional bacterial colonies from the 
suspension. This was underlain by a thin sub-serosal layer of neutrophils (figure 3.2 
A, B). In addition, a few to several neutrophils were found in the lumen of central 
veins and portal veins (figure 3.2 C). Large numbers of neutrophils in the blood 
vessels indicate a release of neutrophils from storage pools (i.e. bone marrow) and a 
neutrophilia – a finding consistent with systemic inflammation. Rarely, individual 
neutrophils were also seen in the sinusoids immediately adjacent to the central veins.  
The PAS reaction highlighted diffuse hepatocellular glycogen accumulation, which 
was most pronounced in centrilobular areas. 
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Figure 3.2: C57BL/6 mouse at 6 hours post intraperitoneal inoculation of faeces 
(1.75 mL/kg) (case No 12L-1393). Liver. (A) Liver parenchyma with capsule, 
exhibiting focal serosal attachment of neutrophils and cellular debris (perihepatitis). 
Underlying the infiltrate is a thin layer of subserosal neutrophils (arrow). (B) Closer 
view of the perihepatitis, showing debris (Db) and bacterial colonies (Ba) from the 
faecal suspension. (C) Liver parenchyma with neutrophils in the lumen of central 
veins (CV) and portal veins (PV). Hepatocytes exhibit cloudy cytoplasmic 
vacuolation consistent with diffuse glycogen accumulation. HE stain. 
A 
B 
C 
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LPS-treated animals did not show any evidence of perihepatitis. However, they 
exhibited more intense leukocyte recruitment into the parenchyma, as represented by 
the presence of increased numbers of disseminated neutrophils between hepatic cords 
(figure 3.3 A&B). Neutrophils were also present in the lumen of central veins and 
portal veins, in similar amounts to those observed in the mice that had undergone 
faecal peritoneal inoculation. In addition, diffuse glycogen loss was observed. This 
was represented by a loss of hepatocellular cytoplasmic vacuolation and the absence 
of PAS positive material within hepatocytes (Figure 3.3 B). 
  
 
Figure 3.3:  C57BL/6 mouse at 6 hours post intraperitoneal inoculation of LPS 
(25mg/kg) (case No 12L-1402). Liver. (A) Small random neutrophil aggregates are 
seen in the parenchyma. Isolated individual necrotic hepatocytes (Nec Hep) are seen. 
There are several neutrophils in the lumen of central veins (CV) and portal veins 
(PV). (B) Closer view of the liver parenchyma, highlighting the increased amount of 
neutrophils between hepatic cords. Hepatocytes do not exhibit cytoplasmic 
vacuolation, consistent with a diffuse loss of glycogen. HE stain. 
B 
A 
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APAP treatment of mice was associated with a variable degree of centrilobular 
hepatocyte loss with the presence of small numbers of degenerate/necrotic 
hepatocytes and/or a variable degree of hydropic degeneration of centrilobular 
hepatocytes. Diffuse loss of hepatocellular glycogen was observed. There was no 
distinct evidence of neutrophil recruitment, i.e. there was no increase in neutrophils 
within veins or hepatic cords (figure 3.4) 
 
 
Figure 3.4:  C57BL/6 mouse at 6 hours post intraperitoneal inoculation of APAP 
(350mg/kg). Liver. (A) Case No 12L-1411, without significant centrilobular cell loss. 
There is evidence of hydropic degeneration of centrilobular hepatocytes (1-2 cell 
layers), represented by swelling of hepatocytes and delineated cytoplasmic vacuoles 
(arrows, V). Scattered centrilobular apoptotic/necrotic hepatocytes and a few 
neutrophils are seen. Endothelial cells (arrows, EC) within the central veins (CV) 
appear activated.  Hepatocytes do not exhibit cytoplasmic vacuolation, consistent 
with a diffuse loss of glycogen. (B) Case No 12L-1412. No glycogen (NG). There is 
marked centrilobular hepatocyte loss (grade II
106
) and hydropic swelling and 
degeneration of remaining hepatocytes (encircled). Blood fills the areas of 
hepatocyte loss. HE stain. 
B 
A 
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2.3.2 Histological findings in Adipose tissue and skeletal muscle  
Mice treated with LPS and faecal inoculation showed variable evidence of neutrophil 
recruitment, represented by the presence of veins in which neutropihls were found in 
the lumen and rolling along (attached to) endothelial cells (figure 3.5). This was 
more frequent in mice that had been inoculated with the faecal suspension, indicating 
an early onset of systemic neutrophil recruitment into these tissues in these animals. 
The latter also showed some degree of serosal inflammation at the surface of the 
perirenal adipose tissue, consistent with peritonitis (see also perihepatitis above 
figure 3.2).  
In LPS treated animals, the skeletal muscle (M gastrocnemius) did not exhibit any 
pathological changes. Mice that had been inoculated with faecal suspension often 
exhibited variable amounts of neutrophils with the lumen of veins (figure 3.6). 
In APAP treated mice and in control mice, adipose tissue and gastrocnemius muscle 
did not exhibit any pathological changes. Occasionally, veins in the subcutis 
contained a few neutrophils and there was a focal inflammatory cell infiltration, but 
this was considered as a local reaction. 
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Figure 3.5:  C57BL/6 mouse at 6 hours post intraperitoneal inoculation of faeces 
(1.75 mL/kg) (case No 12L-1393). A,B Case No 12L-1093. (A) Epididymal adipose 
tissue. Embedded between adipocytes (ApC) are veins that exhibit several 
neutrophils in the lumen. (B) Peri-renal fat with focal serosal neutrophil infiltration 
with admixed bacteria (peritonitis) and veins containing neutrophils in the lumen. 
(C) Case No 12L-401. Epididymal adipose tissue. Vein packed with neutrophils. HE 
stain. 
 
A 
B 
C 
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Figure 3.6:  C57BL/6 mouse at 6 hours post intraperitoneal inoculation of faeces 
(1.75 mL/kg) (case No 12L-1093). Muscle gastrocnemius.  Larger artery with several 
neutrophils in the lumen. HE stain. 
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2.3.3 Histological Findings in Other Tissues of mice inoculated with LPS and APAP  
There was no additional tissue available from mice dosed intra-peritoneally with the 
feacal suspension. However, in animals that had been treated with LPS and APAP, 
other tissues were examined in order to identify any pathological changes consistent 
with a systemic inflammatory response and any associated other changes.  
In lungs, control animals did not show any pathological changes and only rare 
neutrophils were seen within vessel lumina (figure 3.7). In LPS treated animals, 
several neutrophils were generally present in the lumen of veins and arteries (figure 
3.8 (A)). There was also evidence of neutrophil rolling along the endothelium which 
occasionally appeared activated (figure 3.8 B&C). Occasionally, vessels were 
completely packed with neutrophils.  
 
 
 
Figure 3.7: C57BL/6 mouse at 6 hours post intraperitoneal inoculation of saline 
(control animal; case No 12L-1405). Lung. No histological abnormality is 
recognised. Blood vessels do not exhibit neutropils in the lumen. HE stain. 
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Figure 3.8: C57BL/6 mouse at 6 hours post intraperitoneal inoculation of LPS 
(25mg/kg) (case No 12L-401). Lung. (A) Small venules and larger veins are found 
packed with neutropihls. (B) Neutrophils are found rolling along the endothelium 
indicating recruitment into the tissue. (C) Some endothelial cells (EC) appear 
activated (arrows) and there are number neutrophils in the lumen of an artery, some 
of which are seen rolling along the endothelium. HE stain. 
 
 
A 
B 
C 
 
 86 
The Spleen and thymus were also examined in order to assess the potential effect of 
LPS and APAP treatment on the lymphocyte populations.  
In LPS treated animals, the spleen exhibited larger follicles than in control animals, 
and they contained larger numbers of apoptotic cells. Figure 3.9 (A) Control animal; 
(C) LPS treated animal control. The latter were also numerous in the red pulp which 
otherwise exhibited a generally low cellularity and often several variably sized 
aggregates of neutrophils. After APAP treatment, spleens showed a large number of 
apoptotic lymphocytes, both in red pulp and follicles. However, there was no 
evidence of substantial cell loss in the red pulp and follicles generally appeared small 
(no evidence of activation) (Figure 3.10 (C)). 
The thymus of control animals did not show any evidence of involution and only 
scattered apoptotic lymphocytes (Figure 3.10A). The latter were numerous in the 
thymus of LPS and APAP treated animals, in particular in the cortex (Figure 3.10 
B&C). 
The bone marrow was normocellular in all animals, but in LPS and APAP treated 
animals, a few apoptotic cells were observed. 
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Figure 3.9: C57BL/6 mice at 6 hours post intraperitoneal inoculation. Spleen. (A) 
Inoculation with saline (control animal; case No 12L-1405). Follicles are small and 
do not exhibit numerous apoptotic cells. The red pulp exhibits high cellularity. (B) 
Inoculation with LPS (25mg/kg) (Case No -12L-1394). Moderately sized follicles 
with several apoptotic cells. The red pulp exhibits a low cellularity and numerous 
apoptotic cells as well as some neutrophil aggregates. (C) Inoculation with APAP 
(350mg/kg) (case No 12L-1411). Follicles are relatively small, but exhibit numerous 
apoptotic cells. The latter are also seen in the cell rich red pulp . HE stain. 
B 
C 
A 
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Figure 3.10: C57BL/6 mice at 6 hours post intraperitoneal inoculation. Thymus. (A) 
Inoculation with saline (control animal; case No 12L-1405). The cortex exhibits 
occasional individual apoptotic lymphocytes. (B) Inoculation with LPS (25mg/kg) 
(case No. 12L-1393). Numerous disseminated apoptotic lymphocytes are seen, in 
particular within the cortex. (C) Inoculation with APAP (350mg/kg) (case No. 12L-
1411).Numerous apoptotic cells are seen, in particular within the cortex. HE stain. 
A 
B 
C 
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2.3.4 Summary  
The major differences between the two models of murine sepsis (LPS versus faecal 
peritoneal inoculation) are summarised below: 
 After faecal peritoneal inoculation, animals develop an acute suppurative 
peritonitis. This is not seen after LPS treatment. 
 Both models showed evidence of systemic neutrophil recruitment into tissues. 
This was more intense after LPS treatment.  
 Faecal peritoneal inoculation resulted in more substantial evidence of 
neutrophil recruitment into fat and skeletal muscle. 
The histopathological analysis of further tissues from LPS treated animals confirmed 
the lungs as a significant tissue of neutrophil recruitment and thereby a good 
indicator of the systemic inflammatory response in mice, with numerous neutrophils 
in the vessel lumen and rolling along the activated endothelium.  
Both LPS and APAP treated animals showed a significant increase in apoptotic 
lymphocytes in the spleen and thymus, a finding known to be associated with rises in 
TNF-α (particularly in an LPS model of sepsis). 
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2.4 Discussion 
Remick et al
8, 47
  compared the cytokine profile in the murine LPS model of sepsis 
with that of the CLP model and found that the CLP model exhibited a profile that is 
more similar to the one in human sepsis than the LPS model (gradual rising and 
sustained cytokine response) 
8
. Gonnert et al
48
  found a similar response in their 
faecal inoculation model. The analysis of tissues from the faecal inoculation model 
and the LPS model in the present study showed that the differences in the cytokine 
pattern are not reflected by significant differences in the acute histological changes in 
key tissues. In both models, treated animals displayed acute changes consistent with 
an early systemic inflammatory response. This was more pronounced in LPS treated 
mice, which showed more intense features of neutrophil recruitment into tissues such 
as the liver and in particular the lungs. This is most likely due to the greater increase 
of TNF-α and other cytokines (which are known to cause neutrophil aggregation in 
the liver vasculature 
101
) seen in the LPS model 
8
. This similarity indicates that 
despite differences in cytokine increases and profiles in both models, activation of 
neutrophils and endothelial cells and thereby recruitment of neutrophils into tissues 
isn’t as pronounced.  
Parenchymal cell death was not seen in any organ (heart, lungs, liver, kidneys, brain) 
in either model and it is known that TNF-α  in the LPS model peaks beyond 6 hours 8 
and in the faecal model levels normalise before 5 hours
48
, suggesting levels are never 
high enough to induce cell death, but can merely initiate the systemic inflammation. 
Gonnert et al
48
 noted that significant adherence and rolling of neutrophils is only 
seen from 15 hours onwards, at which time detectable levels of cell death were not 
observed either. Principle histopathological changes are similar (i.e. neutrophilia and 
tissue recruitment) so the dichotomy between models must exist beyond 6 hours, i.e. 
acute changes are similar. The use of APAP mice as "positive controls" allowed for 
methodological anomalies with dosing to be ruled out as a contributing factor. APAP 
is known to cause significant release of TNF-α and IL-1 from 100 which contribute to 
hepatocyte necrosis along with direct drug toxicity
101. However negligible neutrophil 
recruitment observed in this study demonstrated that hepatocyte necrosis in this study 
was a direct result of drug toxicity as opposed to immune mediated damage. 
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In the context of human sepsis classification, LPS mice did not meet the 
ACCP/SCCM 
1
 defined sepsis criteria: 
“Whenever SIRS is the result of a confirmed infectious process it is sepsis” 
LPS mice showed no evidence of peritonitis from injection of LPS, whereas faecal 
inoculated mice resulted in an acute suppurative peritonitis induced by the bacteria 
from the inoculum. This shows that the latter model reflects the pathogenesis of 
bacterial sepsis of any origin much better than the LPS model which can be 
considered as a model of "end stage sepsis" when substantial generalised 
endotoxaemia has occurred.  
2.4.1 Neutrophil recruitment into tissues  
Neutrophils are known to be the common first leukocyte to increase in number and 
infiltrate tissues during the inflammatory process induced by bacteria
33
. They migrate 
into tissues through the process of chemotaxis, attracted by chemokines such as IL-8. 
Chemotaxis is directed movement of cells up a chemical a gradient 
105
. The classical 
emigration cascade comprises the elements of capture, rolling, activation and 
adhesion
83
. Neutrophil capture and rolling can be mediated by endothelial cells 
through P-selectin binding PSGL-1, activation may occur through a chemokine (i.e. 
IL-8) and adhesion requires intercellular adhesion molecule-1 (ICAM-1), binding β2 
integrins on the neutrophil 
98
. Rapid cessation of neutrophil emigration which occurs 
remarkably early in the evolution of the acute inflammatory response represents one 
of the earliest events in the resolution process 
107. However, in sepsis models and 
particularly the LPS model, neutrophils often back up blood vessels and over 
recruitment and impaired neutrophil apoptosis leads to their persistence in tissues. 
Flooding the blood with cytokines and chemoattractants in sepsis causes 
inappropriate neutrophil activation associated with a paradoxical inability to recruit 
neutrophils to the site of infection 
98. The recruitment and beginnings of infiltration 
of neutrophils into the tissues in both models was at 6 hours, reflecting the acute 
nature of the inflammatory response.  
It could be suggested that the differences in both models used were reflected by a 
difference in endothelial activation. The faecal model had a tendency to show greater 
numbers of neutrophils in other secondary tissues such as adipose tissue and skeletal 
muscle. Using gene knock-out mice, Andonegui et al
108
 were able to show that 
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endothelium-derived TLR 4 was more important than leukocyte derived TLR 4 in 
LPS-induced neutrophil sequestration into the lungs. Low doses of LPS (0.5 mg/kg) 
induced a dramatic increase in neutrophil sequestration into the lungs of Leukocyte 
TLR 4–/– mice over the first 4 hours and by contrast, endothelial TLR 4–/– mice 
showed very little increase in neutrophil sequestration in the lungs, suggesting that 
endothelial rather than leukocyte TLR 4 was important and further highlighting the 
significant role of endothelial activation in inflammation and sepsis 
108
. Considering 
the histopathological results of the present study, perhaps the key to understanding 
the difference between the models lies in the level, extent and tissue pattern of 
endothelial activation in each, where the more gradual rising sustained level of 
cytokines seen by Gonnert et al
48
, favours a wider, more diffuse systemic response 
and recruitment of leukocytes into tissues.  
2.4.2 Lymphoid organs and inflammation 
Lymphoid organs are known to be vulnerable to apoptosis in human patients with 
sepsis
88
. We observed significant lymphocyte apoptosis in spleen and thymus of LPS 
and APAP treated mice. This finding is known to be associated with rises in TNF-α 
(particularly in the LPS model of sepsis), however these changes would only be 
expected at levels of TNF-α that would also affect the liver and other organs, where 
no significant cell death was detected. Zhang et al 
109
  demonstrated that apoptosis in 
the thymus of mice injected with LPS was mainly mediated by adrenal hormones, 
since adrenalectomy completely inhibited the appearance of apoptosis in mice. In 
contrast, the use of anti-TNF-α antibody only partially inhibited the lymphocyte 
apoptosis, indicating that although contributing it is not the significant cause of 
apoptosis in this species. Similarly, in the LPS and APAP treated animals in the 
present experiments, the apparent lack of parenchymal organ damage would suggest 
that TNF-α levels were not high enough to cause the latter damage, but probably 
contribute towards the apoptosis seen in spleen and thymus. Nonetheless, it is largely 
other mechanisms (such as adrenal hormones) that are governing it. TNF-α 
independent pathways of thymic apoptosis have been previously described in mice 
undergoing CLP 
110
.  Furthermore, apoptosis in the spleen has been shown to be an 
important pathogenic step in HMGB1 sepsis related lethality
111
.  The LPS and APAP 
treated mice had similar levels of lymphoid apoptosis, and in the case of the APAP 
treated animals alongside toxic liver damage; accordingly, it is debatable as to 
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whether or not TNF-α is inducing apoptosis on its own or whether similar adrenal 
mechanisms are triggered after APAP treatment. Without definitive quantification of 
serum cytokine levels and assessment of adrenal hormones, this cannot be concluded. 
Ayala et al
104
 demonstrated a differential induction of apoptosis in polymicrobial 
sepsis. The thymus was often affected a lot earlier than the bone marrow (detectable 
changes were at 4 hours and 24 hours respectively). It was concluded that different 
from thymic cells, cells in the bone marrow are not affected directly by 
glucocorticoids or TNF-α, to the same extent, released during sepsis. This is 
consistent with our results where the degree of apoptosis in thymus and spleen was 
far higher than that in the bone marrow.  
2.4.3 APAP and drug toxicity 
The initial morphological changes in the liver following APAP overdose include 
glycogen loss and vacuolisation of centrilobular hepatocytes, and single-cell necrosis 
of hepatocytes, pyknotic nuclei and eosinophilic cytoplasm 
96
. In the present study, 
the presence of hepatocyte necrosis was detected at 6 hours. It has been shown that 
TNF-α and IL-l play an important role in modulating APAP induced liver injury. 
Altering the actions of either of these cytokines by increasing or decreasing their 
levels by specific modulators can suppress or enhance the severity of these effects
100
. 
This highlights that, like the LPS model of sepsis, TNF-α plays a crucial role in 
mediating organ damage.  
2.4.4 Summary & further research  
In chapter 1 the important mechanisms and cell signalling pathways behind the 
inflammatory response were studied. The results demonstrated that there was a key 
species variation in response to LPS. In this chapter, comparative analysis of two 
well characterised murine models of sepsis (LPS and faecal peritoneal inoculation) 
has shown further that difficulty in recapitulating a similar environment of human 
sepsis in rodents widens the gap that the translational bridge must cross. This makes 
it difficult to accurately assess whether or not treatments developed in vivo will be 
efficacious in humans. Both models showed a similar level of changes consistent 
with an acute systemic inflammatory response at 6 hours post treatment, which 
suggests that despite the known differences in cytokine profiles between these two 
models, the dichotomy must exist and represent themselves later in histological 
changes. The initiating steps are fairly similar (i.e. neutrophilia and recruitment into 
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tissues), but it may be the maintenance and resolution of these events later on in the 
course of the disease that differ.  The faecal inoculation model is known to cause 
persistent inflammatory changes weeks later from the insult (persistent neutrophil & 
macrophage infiltration along with abnormal lymphocytes
48
), whereas similar 
changes are not seen with LPS dosing. 
This chapter also highlighted the importance of cellular necrosis and apoptosis in the 
septic process. In the general introduction a novel biomarker of this (caspase cleaved 
and uncleaved CK18) was identified and results and discussion in this chapter have 
identified its potential application in a clinical setting. Similarly HMGB1 (a late pro-
inflammatory cytokine), would indicate a prolonged inflammatory process and in 
combination with CK18 may give an invaluable insight into the internal environment 
and status of damage within this group of patients. 
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Chapter 4: 
Analysis of novel biomarkers of 
sepsis in human serum 
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4. Analysis of novel biomarkers of sepsis in human serum 
4.1 Introduction  
Translational medicine is the progression of turning appropriate discoveries about 
processes and physiology, into therapeutic interventions that can treat patients 
effectively. Solid evidence has to support clinical decision making and treatments. 
Chapter 2 & 3 have looked at the benefits and drawbacks of in vitro and in vivo 
techniques in the study of inflammation and sepsis, and highlighted the significance 
of species variation in response to inflammatory insults, early histological changes 
associated with sepsis and identified niches for the use of potential novel biomarkers 
in clinical medicine.  
HMGB1 a late pro-inflammatory cytokine and product of NFκB signalling It is an 
ubiquitously expressed protein that has recently been discovered as a marker of 
inflammation in humans and an important therapeutic target for sepsis in 
endotoxaemic mice 
34
 (see General introduction 1.2.4). CK18 has also been 
identified as a novel way of measuring apoptosis (caspase cleaved CK18) and 
necrosis (full length CK18), known important processes in sepsis and indicators of 
severity of illness 
88
 (see section 1.4).These novel biomarkers will be investigated to 
see whether or not they are useful indicators of outcome and prognosis in patients 
with sepsis admitted to ICU. Furthermore pre-study analysis has highlighted their use 
in another sub-group of patients.  
4.1.1 Liver disease and sepsis 
Liver disease is a significant problem in the UK; with non-relenting high mortality 
rates and an increasing association with increasing age 
112
 . Although it has a varied 
aetiology the majority of patients develop it secondary to alcohol and this is also a 
major contributing factor to the worsening progression of other liver diseases (i.e. 
Hepatitis C) 
113
. Their presentation to the ICU is varied and provides physicians and 
anaesthetists with questionable problems about management, and difficulties in 
prognosis. Alcoholic liver disease (ALD) in particular is showing an increase in 
admission and mortality
114
 . Not only does liver disease as a primary presentation 
cause these problems, but also when it presents as an underlying process in patients 
with other primary complaints i.e. sepsis 
115
. 
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The pathogenesis of ALD has been attributed to altered Kupffer cell activity, 
oxidative stress and innate immune responses caused by gut derived endotoxin in 
response to ethanol consumption
116
. With this better understanding treatments for it 
are becoming more efficacious and the emphasis should now lie on the earlier 
detection and better understanding of liver damage, in order to prevent a critical 
admission to the ICU with decompensated failure. 
In the review by Berry et al 
117
, they identified that the most worrying complications 
of ALD that result in ICU admission are “variceal bleeding”, “hepatorenal 
syndrome” and “Acute on chronic liver failure”. However, although mortality has 
somewhat decreased with these conditions, with the instigation of newer more 
evidence-based treatments, mortality still remains high 
118
 . Berry et al 
117
 conclude 
that better understanding and identification is needed in order to be able to treat these 
patients as survival is not improving 
4.1.2 Pre-study retrospective analysis  
An audit was carried out at the Royal Liverpool University Hospital to assess the 
incidence of different aetiologies of liver disease in patients admitted to the critical 
care unit. Patients admitted between January 2008 and July 2011, were included and 
various admission parameters for each patient were recorded including 
haematological, electrolyte, liver function and clotting values. These were recorded 
along with APACHE II scores, length of stay, and evidence of diagnostic imaging 
(i.e. ultrasound), ventilator and organ support and overall hospital mortality. 
4.1.4 Results 
ALD patients were found to have lower blood sodium levels (Mean 135.56; CI 
133.41-137.71. P = 0.004) and were hypocalcaemic (1.93; CI 1.88-1.99), and had 
more severe derangements in various liver function tests (P < 0.001) and clotting 
studies (P < 0.001), see table 4.1 and 4.2 below. ALD patients also had significantly 
longer ITU stays (P <0.001) and higher mortality rates (45.45% ALD versus 13.2% 
NALD) which is in keeping with the literature 
118
. 
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Liver 
function test 
 Alcoholic 
liver 
disease  
(N=66) 
 Non-
Alcoholi
c liver 
disease 
(N=53) 
  
 Normal 
value 
Mean Confidenc
e interval 
Mean  Confidenc
e interval 
P 
value  
GGT <75iu/L 127.12 92.92; 
161.32 
67.36 32.64; 
102.07 
<0.00
1 
ALP 30-
150iu/L 
101.52 86.7; 
116.33 
 
75.21 59.28; 
91.13 
=0.00
1 
ALT  
3-35iu/L 
82.33 44.88; 
119.78 
197.6 17.06; 
378.15 
=0.18
4 
Albumin 36-52 g/L 82.17 58.55; 
105.78 
22.69 9.3; 
36.09 
<0.00
1 
Bilirubin 3-
17mmol/
L 
24.39 22.55; 
26.24 
 
33.74 31.75; 
35.72 
<0.00
1 
Table 4.1: Table showing the admitting Liver function tests (LFTs) of patients 
admitted to ICU with a primary liver complaint. Patients were divided into two 
groups depending on whether or not that had presence of ALD.  
 
Clotting 
studies  
 Alcoholic 
liver 
disease 
(N=66) 
Non-
Alcoholi
c liver 
disease 
(N=53) 
  
Confidence 
interval 
Mean  Confidence 
interval 
Mean  Confidence 
interval 
P value  
PT 17.22 14.23; 
20.21 
21.89 19.76; 
24.03 
<0.001 
APTT 34.54 29.23; 
39.86 
43.74 40.12; 
47.36 
<0.001 
INR 2.22 0.89; 
1.26 
1.35 1.21; 
1.49 
<0.001 
Fibrinogen 2.43 2.18; 
2.68 
1.74 1.44; 
2.05 
<0.001 
Platelets 1.08 150.19; 
193.8 
103.83 87.66 
120.01 
<0.001 
Table 4.2: Table showing the admitting Clotting studies (LFTs) of patients admitted 
to ICU with a primary liver complaint. Patients were divided into two groups 
depending on whether or not that had presence of ALD.  
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4.1.3 Receiver operated characteristic curve analysis 
This analysis allows a test to be evaluated for its usefulness in distinguishing 
between positive and negative results. It uses the sensitivity and specificity of an 
investigation in order to generate a curve, where the area underneath represents the 
efficacy or discriminatory value of that test 
119
. Receiver operated curve (ROC) 
analysis revealed that current biochemical markers (ALT, PT, GGT, Albumin) are 
not sensitive and specific enough in detecting failure associated with ALD, when 
using fatality as the measured outcome. Pro-thrombin time yielded the best area 
under the curve with 80.4% in ALD versus 71.7% in NALD, see figure 4.1 A & B. 
None of the markers was discriminatory for determining type of liver damage. 
4.1.4 Conclusions of the pre-study analysis  
The results suggest that currently used markers of liver disease are neither sensitive 
nor specific enough, particularly in critically ill patients suffering from failure 
secondary to ALD. More research is needed to develop novel biomarkers to better 
prognosticate outcome. Aetiology of acute-on-chronic liver failure plays a major role 
in determining outcome, and subgroups of liver patients should be analysed 
individually.  
4.1.5 Applications of HMGB1 and CK18 
HMGB1 and CK18 have shown to be serum based markers released depending on 
the type of damage (necrotic versus apoptotic) and differ in acute liver damage of 
different origin
38, 39, 55
. ALD has been shown to have two main routes of liver failure 
either decomposition or acute on chronic failure (AoCF) i.e. patients with ALD who 
develop a sepsis
117
. Comparing these patients with patients with no ALD and sepsis 
alone will give an understanding about the mechanistic differences in the pathologies 
of liver damage in these diseases (i.e. hepatocyte damage) and whether or not serum 
biomarkers (HMGB1 and CK18) can be used in a novel way to represent these 
differences. Inflammation is an important process in the development of cirrhosis 
and sepsis
11, 88, 116
, so serum biomarker HMGB1 should be found in the serum of 
these patients. Necrosis and apoptosis are important cellular processes that have been 
shown to be significant in sepsis both in human
88, 91
 and animal models (see chapter 
3), indicating that cleaved and uncleaved CK18 could have an application along with 
HMGB1 in this group of patients.  
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Figure 4.1: graphs showing receiver operated characteristic (ROC) curve analysis 
for admitting pro-thrombin time in patients admitted to ICU with a primary liver 
complaint and using fatality as outcome. Patients were divided into groups 
depending on whether or not they had ALD (bottom B) or no ALD (top A)  
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4.1.6 Aims of the chapter 
Pre-study analysis has shown that there is a need for novel biomarkers in a defined 
group of patients in ICU. These biomarkers could potentially help better discriminate 
between types of liver damage and sepsis severity in these patients and help better 
prognosticate and predict outcome. The study has also shown that no individual 
biomarker is completely sensitive or specific enough, and that perhaps the way 
forward is the development of biomarker combinations, or adding new biomarkers to 
ones that are already widely used. The hypothesis is stated below: 
“Serum levels of sepsis biomarkers HMGB1 and CK18 vary with the underlying 
liver condition: Serum HMGB-1 and CK18 levels differ in patients with sepsis 
depending on their underlying liver condition. Two groups of critically ill patients 
will be compared: 1. Patients with sepsis and no history of liver disease 2. Patients 
with sepsis and known liver disease. Results will be compared to healthy volunteers 
(controls) and patients admitted to ICU patients without sepsis or underlying liver 
disease. .” 
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4.2 Materials and Methods 
4.2.1 Materials   
HMGB1 ELISA plates for the detection of the protein in human serum were obtained 
from Innovation beyond limits (IBL) international (ST51011). M30 Apoptosense® 
ELISA for the detection of epithelial apoptosis and caspase cleaved K18 was bought 
from PEVIVA along with the M65 Epideath® ELISA for the detection of epithelial 
cell death and full length K18. The revelation® software and MRX plate reader 
where from Dynex technologies.  Patient samples where kindly donated by Professor 
Cheng-Hock Toh. The Department of clinical infection, microbiology and 
immunology, University of Liverpool.  
4.2.3 Statistics used in the analysis of results 
Statistics and figures were done using StatsDirect® and Microsoft excel®. 
For analysis of the differences of serum biomarkers (HMGB1 and cleaved and 
uncleaved CK18) between patients admitted to ICU and healthy controls, a Mann-
Whitney U test was used. This test was also used to test for differences between 
serum concentrations of HMGB1 and CK18 between defined patient groups. The 
data was non-normally distributed, indicating the need for use of a non-parametric 
test. Furthermore, the Mann-Whitney U test is useful for assessing whether one of 
two samples of independent observations tends to have larger values than the other 
(i.e. whether one group of patients has a higher serum concentration of serum 
biomarker than the other). Values of <0.05 are considered statistically significant. 
For comparison of cleaved and uncleaved CK18 with a patient group the Kruskall-
Wallis test was used as again the data was non-normally distributed but coming from 
the same sample. The test compares the medians of two or more samples to 
determine if the samples have come from different populations. 
4.2.3 Patient recruitment and basic characteristics  
Patient serum was recruited from patients admitted to ICU between 2008-2012. All 
patients gave consent and collection was in line with the Local and National research 
ethics (L/NREC) guidelines. Serum will be analysed from patients in each of the 
following groups: 
 
 
 105 
Patients with; 
 Alcoholic liver disease  
 Sepsis with no liver dysfunction 
 Sepsis with liver dysfunction  
 Alcoholic liver disease with co-morbid sepsis 
Patients were included and excluded based on the following criteria: 
Inclusion Criteria: 
 Patients that fell into one of the specified groups identified above and who 
were admitted to the intensive care unit at the Royal Liverpool University 
Hospital. 
 Patients with Sepsis who met the SIRS criteria set out by the ACCP/SCCM1 
 Patients with Alcoholic liver disease who had significantly deranged liver 
function and had a Child-Pugh score of A or more (Child-Pugh scoring
120
)  
 Patients with sepsis induced liver dysfunction who met the SIRS criteria and 
who had significant deranged liver function. 
 Patients with Alcoholic liver disease (Child-Pugh of A or more) who had 
evidence of sepsis and met the SIRS criteria. An example of this type of 
patient, would be an alcoholic liver disease patient (liver function twice that 
of the normal value) admitted to ICU with spontaneous bacterial peritonitis 
and decompensated liver failure. 
Exclusion criteria 
 Patients under the age of 18 or over the age of 90. 
 Patients who had co-morbid HIV/ hepatitis A, B, C or other significant 
liver/system chronic infectious states.  
 Patients who had Liver failure secondary to causes other than sepsis or 
alcohol excess. 
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The serum was initially collected for another study but patients had given consent for 
serum to be kept and allowed for use in further research. It was stored at -80⁰C and 
thawed completely before being aliquoted for each experiment. The number of days 
used in these analysis was three (1=admitting, 2=second & 3=discharge or last 
samples taken).  Basic patient characteristics are summarised below (table 4.3). 
Patients where matched based on age, sex, APACHE II and their medical records, so 
that patients in each group where comparable and to remove as much as possible 
confounding variables. All the ALD patients had a child-pugh score of (B-C). The 
scoring system is given in table 12. 
Patient 
group  
N Age mean 
& (range) 
Sex ratio 
(M:F) 
APACE II 
mean & 
(range) 
Length of stay 
mean & 
(range) 
ICU 
mortality % 
ALD 4 49.5   
(38-62) 
1:1 17.25 (8-24) 16 (2-20) 25% 
ALD & 
Sepsis 
3 60  
(60-62) 
2:1 15.5 (11-20) 17 (8-17) 66% 
Sepsis 4 58  
(41-85) 
3:1 21 (17-32) 4.5 (3-4) 50% 
No ALD 
no Sepsis 
4 58  
(52-61) 
1:1 21.3(9-22) 3 (2-4) 0% 
Healthy 
controls  
5 48.3 (40-
59) 
2:3 N/A N/A N/A 
Table 4.3: Basic characteristics of patients in defined groups and healthy controls. 
 
 
 
Table 4.4: Child-Pugh scoring system for cirrhosis severity
120
 
Score: 
 5-6 points = Grade A 
 7-9 points = Grade B 
 10-15 points = Grade C 
Score 1 points 2 points  3 points  
bilirubin (micromol/l) <34 34-50 >50 
albumin (g/l) >35 28-35 <28 
PT (seconds prolonged) <4 4-6 >6 
encephalopathy none mild marked 
Ascites none mild marked 
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4.2.4 Enzyme linked immunosorbant assay (ELISA) for the quantitative 
determination of total HMGB1 in patient serum  
The test procedure provided with the plate and reagents (IBL international) was 
followed. 100µl of dilutent buffer was pipetted into each well of the plate using a 
multichannel pipette. Then 10µl of each serum sample, standard or positive control 
was put into respective wells and the plate was gently agitated for 30 seconds. The 
plate was then covered and incubated overnight at 37⁰C. The plate was then washed 
5 times in diluted wash buffer and excess solution was removed by tapping the plate 
on the lab bench. The plate was then incubated for 2 hours at 25⁰C with 100µl of 
enzyme conjugate in each well. Afterwards the plate was washed again 5 times and 
tapped on the lab bench to remove excess solution. 100µl of Enzyme conjugate was 
pipetted into each freshly washed and dried well and covered in foil and incubated at 
25⁰C for 2 hours. The wash steps where repeated like before. 100µl of colour 
solution was pipette into each well and incubated at room temperature in the dark for 
30 minutes before 100µl of stop solution was added. The plate was left for 5 minutes 
before being read on a plate reader using the Revelation® software using a preset 
program. 
4.2.5 M30 Apoptosense® ELISA for the quantitative determination of cleaved CK-
18 in patient serum 
The test procedure provided with the plate and reagents (PEVIVA) was followed and 
is summarised in figure 4.2. 
4.2.6 M65 Epideath® ELISA for the quantitative determination of full length CK-
18 in patient serum 
The test procedure provided with the plate and reagents (PEVIVA) was followed and 
is summarised in figure 4.3. 
4.2.7 Optimization  
Both ELISAs where initially carried out using neat samples. However, many of the 
concentrations measured fell off the standard curve as they were too high. A 1:10 
dilution was done by mixing 5µl of sample with 45µl of standard A (which contained 
no protein) in a freshly labelled Eppendorf tube. Samples were then vortexed and 
then 25µl was loaded onto each well. 
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Figure 4.2: Flowchart taken from protocol provided by PEVIVA summarising the 
protocol for the M30 Apoptosense® ELISA for the detection of caspase cleaved 
CK18. 
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Figure 4.3: Flowchart taken from protocol provided by PEVIVA summarising the 
protocol for the M65 Epideath® ELISA for the detection of full length CK18. 
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4.3 Results 
4.3.1 Serum total HMGB1 and CK-18 cleaved and uncleaved in the serum of 
healthy controls   
Five healthy controls (characteristics defined in table 4.3) were recruited and a single 
serum sample was taken in order to detect serum total HMGB1 and cleaved and 
uncleaved CK18. Table 4.5-4.7 provides this information along with the ICU 
admitting day levels of the defined patient groups. Mann Whitney U testing showed 
that there was a significant difference (p<0.05) between healthy controls and patients 
admitted to ICU. 
 
 
 Day N Range Mean SD Mann Whitney U test 
(compared with healthy 
controls) 
Healthy 
controls 
1 4 0.8-2.2 1.576 0.59  
ALD 1 4 2.91-15.33 7.14 4.63 0.0286 
ALD & 
Sepsis 
1 3 10.64-11.84 11.17 0.61 0.0286 
Sepsis 1 4 6.79-33.27 17.60 4.21 0.0286 
No ALD 
no sepsis 
1 4 7.27-21.99 13.70 6.12 0.0286 
Table 4.5: Serum total HMGB1 (ng/ml) in healthy controls compared with ICU 
admitting day of defined patients groups. Mann Whitney U test was done in order to 
look for statistical differences. A levels <0.05 was significant.  Means are given with 
the range, standard deviation (SD) and P value. Statistical differences were detected 
between all patient groups and healthy controls. 
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 Day N Range Mean SD Mann Whitney 
U test 
(compared with 
healthy 
controls) 
Healthy 
controls 
1 4 332-427 384.4 37.86  
ALD 1 4 849.72-2316.63 1538.01 665.58 0.0159 
ALD & 
Sepsis 
1 3 911.07-1305.81 781.883 599.0604 0.5714 
Sepsis 1 4 920.19-1468.01 1199.78 249.065 0.0159 
No ALD 
no sepsis 
1 4 1210.5-2712.7 1664.705 712.606 0.0159 
Table 4.6: serum cleaved CK18 (U/L) in healthy controls compared with ICU 
admitting day of defined patients groups. Mann Whitney U test was done in order to 
look for statistical differences. A levels <0.05 was significant.  Means are given with 
the range, standard deviation (SD) and P value. Statistical differences were detected 
between all patient groups and healthy controls. 
 
 Day N Range Mean SD Mann Whitney 
U test 
(compared with 
healthy 
controls) 
Healthy 
controls 
1 4 76-289 154 90.00  
ALD 1 4 1567.18-6910.37 3111.224 1990.263 0.043 
ALD & 
Sepsis 
1 3 911.07-1305.81 1850.092 524.5204 0.043 
Sepsis 1 4 896.9-2382.84- 1347.121 667.1293 0.043 
No ALD no 
sepsis 
1 4 289.871-8097.00 2687.94 268.7 0.043 
Table 4.7: serum uncleaved CK18 (U/L) in healthy controls compared with ICU 
admitting day of defined patients groups. Mann Whitney U test was done in order to 
look for statistical differences. A levels <0.05 was significant.  Means are given with 
the range, standard deviation (SD) and P value. Statistical differences were detected 
between all patient groups and healthy controls. 
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4.3.2 Serum total HMGB1 (ng/ml) and CK-18 (U/L) cleaved and uncleaved in the 
serum of patients with ALD 
Serum total HMGB1 (ng/ml) was measure in patients with ALD and no sepsis (N=4) 
over their stay in ICU. Samples included admitting (1), second (2) and last day (3). 
Patients had a significantly elevated (p=0.0286) total HMGB1 on their admitting day 
(Mean 7.14 ng/ml SD 4.63) compared with healthy controls. An elevation of 
HMGB1 between day 1 and 2 was associated with worsening liver function tests 
(LFTs) and increase in serum urea and creatinine on those days. A rise in serum total 
HMGB1 between days 2 to 3 were associated with a fatal outcome in one of the 
patients (4.503ng/ml to 9.478ng/ml). However, a higher concentration on any other 
day did not indicate a poorer outcome as one patient almost doubled between days 1 
to 2, but had a good outcome (15.33ng/ml to 29. 865ng/ml). See Figure 4.4 (A) for a 
line graph of the mean serum total HMGB1 values in those days in patients with 
decompensated ALD. 
The same samples where measured for serum cleaved and uncleaved CK18 (U/L). 
Patients showed a significant increase on admitting values for cleaved (Mean 
1538.01 U/L SD 665.58) and uncleaved (Mean 3111.224 U/L SD 1990.263) CK18 
(p=0.0159 & 0.043 respectively) compared to healthy controls. Patients in this group 
showed visibly higher levels of uncleaved CK18 compared to cleaved CK18 (figure 
4.4 (B)), indicating higher levels of necrosis. However, these differences were not 
significant (see table 4.8). Three out of the four patients were admitted with variceal 
haemorrhage while the fourth was admitted with worsening liver function tests and 
alcohol withdraw. 
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Figure 4.4: (A) Line graph showing the mean (N=4) serum total HMGB1 (ng/ml) in 
the admitting, second and discharge day of patients with decompensated alcoholic 
liver disease (ALD). Means are plotted with Standard error of the mean (SEM). 
Trend demonstrates an increase in serum total HMGB1 between days 1 and 2 and a 
fall on discharge day.  X axis is the serum concentration of HMGB1 and Y axis is 
Day. (B) Bar chart showing the Mean (N=4) serum cleaved/uncleaved CK18 (U/L) 
in the admitting, second and last day of patients with decompensated ALD. Means 
are plotted with SEM. X axis is serum concentration of cleaved/uncleaved CK18 and 
Y axis day. Blue = cleaved CK18 & Red= uncleaved CK18. Graph shows a 
substantial difference between cleaved and uncleaved CK18 in this patient group and 
the general trend is a rise between days 1 and 2, with a fall on last day. 
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 D
a
y 
N CK18 
(U/L) 
Range Mean SD Kruskall 
Wallis for 
cleaved versus 
uncleaved 
CK18 (U/L) 
Decompensated 
ALD  (N=4) 
 1 4 Cleaved 849.72-
2316.63 
1538.008 665.5797 0.0894 
Uncleaved 1567.18-
6910.37 
3111.224 1990.263 
 2 4 Cleaved 920.67-
2016.50 
1833.43 795.0031 0.0894 
Uncleaved 10701.627-
11610.94 
4577.693 3384.91 
 3 3 Cleaved 1295.16-
1674.18 
1437.41 206.433 0.4386 
Uncleaved 981.686-
4100.74 
2501.34 1210.182 
Table 4.8: Serum cleaved and uncleaved CK18 (U/L) in the ICU admitting, second 
and last days of patients with decompensated ALD. Mean values are given with the 
range and standard deviation (SD). Kuskall Wallis test was used to test for a 
significant difference between levels of cleaved and uncleaved in CK18 in each 
individual patient. There was no significant difference detected between values.  
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4.3.3 Serum total HMGB1 (ng/ml) and CK-18 (U/L) cleaved and uncleaved in the 
serum of patients with ALD & sepsis 
Serum total HMGB1 (ng/ml) was measured in patients with ALD and sepsis (N=3) 
over their stay in ICU. Samples included admitting (1), second (2) and last day (3). 
Patients had a significant elevated (p=0.0286) total HMGB1 on their admitting day 
(Mean 11.14ng/ml SD 0.61) compared with healthy controls. An elevation of 
HMGB1 between day 1 and 2 was associated with worsening liver function tests 
(LFTs) and increase in serum urea and creatinine on those days, although the 
elevation of HMGB1 did not reflect the magnitude of increase in these routine 
chemistries (LFTS and serum urea and creatinine doubled while there was only a 
mild increase in total HMGB1). A fall in serum total HMGB1 between days 2 and 3 
was associated with a poorer outcome in two patients (i.e. 7.836ng/ml to 6.1ng/ml 
and 15.181ng/ml to 10.442ng/ml). See Figure 4.5 (A) for a line graph of the mean 
HMGB1 in those days in patients with ALD and sepsis. 
The same samples were measured for serum cleaved and uncleaved CK18. Patients 
showed a visible increases on admitting values for cleaved (Mean 781.883 U/L SD 
599.0604) and uncleaved (Mean 1850.092 U/L SD 524.5204) CK18 (p=0.5714 & 
0.043 respectively) compared to healthy controls. Patients in this group showed 
visibly higher levels of uncleaved CK18 compared to cleaved CK18 (figure 4.5 (B)), 
indicating higher levels of necrosis. The difference is only significant on the 
admitting day (p=0.0389) (see table 4.9). 
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Figure 4.5: (A) Line graph showing the mean (N=3) Serum total HMGB1 (ng/ml) in 
the admitting, second and last days of patients with ALD & sepsis. Means are plotted 
with Standard error of the mean (SEM).  X axis is the serum concentration of 
HMGB1 (ng/ml) and Y axis is Day. Trend demonstrates slight increase in serum total 
HMGB1 (ng/ml) between day 1 and 2 and fall on the last day. (B) Bar chart showing 
the Mean (N=3) serum cleaved/uncleaved CK18 in the admitting, second and last 
days of patients with ALD & sepsis. Means are plotted with SEM. X axis is serum 
concentration of cleaved/uncleaved CK18 and Y axis day. Blue = cleaved CK18 & 
Red= uncleaved CK18. There appears to be visibly higher levels of uncleaved CK18 
(U/L) compared to cleaved on all three days. 
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 Day N CK18 
(U/L) 
Range Mean SD Kruskall 
Wallis for 
cleaved 
versus 
uncleaved 
CK18 (U/L) 
ALD & 
sepsis 
(N=3) 
 1 3 Cleaved 911.07-
1305.81 
781.883 599.0604 0.0389 
Uncleaved 1390.12-
2518.993 
1848.76 524.5204 
 2 3 Cleaved 1040.01-
1747.35 
1402.813 354.0236 0.3017 
Uncleaved 1040.746-
5399.037 
2477.43 1701.286 
 3 3 Cleaved 1004-
1284.41 
1102.793 157.4872 0.6056 
Uncleaved 399.977-
3490.914 
1569.71 1285.104 
Table 4.9: serum cleaved and uncleaved CK18 in the ICU admitting day of patients 
with ALD & sepsis. Mean values are given with the range and standard deviation 
(SD). Kuskall Wallis test was used to test for a significant difference between levels 
of cleaved and uncleaved in CK18 in each individual patient. No significant 
differences between CK18 (U/L) were detected apart from the admitting day. 
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4.3.5 Comparative analysis of serum total HMGB1 (ng/ml) and serum 
cleaved/uncleaved CK18 (U/L) in patients decompensated ALD versus patients 
with ALD and sepsis  
Serum total HMGB1 was measured in patients with decompensated ALD (N=4) and 
patients with ALD and sepsis (N=3) over their stay in ICU. Samples included 
admitting (1), second (2) and last day (3).  Patients with ALD and sepsis had higher 
admitting levels of total HMGB1 (11.17ng/ml SD 0.61) compared with patients with 
decompensated ALD (Mean 7.14ng/ml SD 4.63) .This was a similar pattern for all 
other measured days (figure 4.6). This is an expected observation as HMGB1 levels 
are known to increase with sepsis, however, the difference between levels were not 
significant (table 4.10). 
Patients with decompensated ALD were found to have both higher levels of cleaved 
and considerably higher levels of uncleaved CK18 than patients admitted with ALD 
and sepsis (figure 4.7 A & B). This indicates that the levels of apoptosis and more 
importantly necrosis are higher in the patient group. Although these values are not 
significant (table 4.11), they are approaching a significant level suggesting that 
perhaps the sample size is too small. 
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Figure 4.6: Bar chart showing the Mean serum total HMGB1 (ng/ml) in patients 
with decompensated ALD (N=4, Blue) and patients with ALD and sepsis (N=3, Red). 
Means of admitting, second and last days are plotted with SEM. X axis is the serum 
total HMGB1(ng/ml) and Y axis is the day. Trend shows that there is a mean 
increase in HMGB1 in both patient groups between day 1 and 2 and a fall from day 
2 to 3. Patients with ALD and sepsis have visibly higher levels of serum total 
HMGB1 on all days. 
 
 
 Day N Range Mean  SD Mann Whitney U 
test 
ALD No 
sepsis  
 1 4 3.30-15.33 7.14 5.28 Day 1 0.4 
 2 4 3.99-29.87 11.65 11.65 
 3 3 7.05-9.48 8.50 8.50 Day 2  0.63 
ALD & 
sepsis(N=4) 
 1 3 10.64-11.84 11.174333 0.61 
 2 3 7.84-15.56 12.86 4.35 Day 3 0.7 
 3 3 6.1-16.85 11.13 5.41 
 
Table 4.10: Table showing significance testing, using the Mann-Whitney U test, on 
serum total HMGB1 (ng/ml) in patients with decompensated ALD versus patients 
with ALD and sepsis. Mean values are given with the range and standard deviation 
(SD).  There are no significant differences.  
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Figure 4.7: Top (A) Bar chart showing the mean serum cleaved CK18 (U/L) in 
patients with decompensated ALD (N=4, Blue) and patients with ALD and sepsis 
(N=3, Red). Patients with decompensated ALD have mildly higher levels than 
patients with ALD and sepsis. Bottom (B) Bar chart showing the Mean serum 
uncleaved CK18 in patients with decompensated ALD (blue) and ALD & sepsis (red) 
Patients with decompensated ALD have visibly higher levels of uncleaved CK18 than 
patients with ALD & sepsis. Means of admitting, second and discharge days to ICU 
are plotted with SEM. X axis is cleaved/uncleaved CK18 in U/L and Y axis is the day. 
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 Day N CK18 
(U/L) 
Range Mean SD Mann 
Whitney U 
(ALD no 
sepsis versus 
ALD & 
sepsis) 
ALD No 
sepsis  
(N=4) 
 1 4 Cleaved 849.72-
2316.63 
1538.008 665.5797 Day 
1 
C= 
0.4 
Uncleaved 1567.18
-
6910.37 
3111.224 1990.263 
 2 4 Cleaved 920.67-
2016.50 
1833.43 795.0031 UC= 
0.1 
Uncleaved 10701.6
27-
11610.9
4 
4577.693 3384.91 
 3 3 Cleaved 1295.16
-
1674.18 
1437.41 206.433 Day 
2  
C= 
0.4 
Uncleaved 981.686
-
4100.74 
2501.34 1210.182 
ALD & 
sepsis 
(N=3) 
 1 3 Cleaved 911.07-
1305.81 
781.883 599.0604 UC= 
0.18 
Uncleaved 1390.12
-
2518.99
3 
1848.76 524.5204 
 2 3 Cleaved 1040.01
-
1747.35 
1402.813 354.0236 Day 
3 
C= 
0.63 
Uncleaved 1040.74
6-
5399.03
7 
2477.43 1701.286 
 3 3 Cleaved 1004-
1284.41 
1102.793 157.4872 UC= 
0.18 
Uncleaved 399.977
-
3490.91
4 
1569.71 1285.104 
Table 4.11: Table showing results of Mann Whitney U testing on serum cleaved 
versus uncleaved CK18 in patients with decompensated ALD versus patients with 
ALD and sepsis. Mean values are given with the range and standard deviation (SD). 
There are no significant differences. 
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4.3.6 Serum total HMGB1 (ng/ml) and CK-18 (U/L) cleaved and uncleaved in the 
serum of patients with Sepsis  
Serum total HMGB1 (ng/ml) was measured in patients with sepsis (N=4) over their 
stay in ICU. Samples included admitting (1), second (2) and last day (3). Patients had 
an elevated HMGB1 (Mean 17.60 ng/ml SD 4.21) on their admitting day (p=0.0286) 
compared with healthy controls. A rise was seen in all patients between day 1 to 2 
and this was associated with worsening LFTs and serum urea and creatinine. All 
patients exhibited a decline between day 2 and discharge day. (Figure 4.8 (A)).  The 
overall ICU % mortality rate in this group of patients was 50%. 
The same samples where measured for serum cleaved and uncleaved CK18 (U/L). 
Patients showed visible increases on admitting values for cleaved (Mean 1199.78 
U/L SD 249.065) and uncleaved (Mean 1347.121 U/L SD 667.1293) CK18 
compared to healthy controls (p=0.0159 & 0.0143 respectively).  There was a visible 
increase in uncleaved CK18 between day 1 to 2 but this was not significant (figure 
4.9 (B)). There were no significant differences between values for cleaved and 
uncleaved CK18 on any day. See table 4.12. 
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Figure 4.9: Top (A) Line graph showing the mean (N=4) serum total HMGB1 
(ng/ml) in the admitting, second and discharge day of patients with sepsis. Means are 
plotted with Standard error of the mean (SEM).  X axis is the serum concentration of 
HMGB1 (ng/ml) and Y axis is Day. Trend shows an increase in HMGB1 between 
days 1 and 2 and a fall on the last day. Bottom (B) Bar chart showing the Mean 
(N=4) serum cleaved/uncleaved CK18 (U/L) in the admitting, second and last day of 
patients with sepsis. Means are plotted with SEM. X axis is serum concentration of 
cleaved/uncleaved CK18 (U/L) and Y axis day. Blue = cleaved CK18 & Red= 
uncleaved CK18. Patients have higher levels of uncleaved CK18 compared to 
cleaved CK18, particularly on day 2. Same trend is observed with an increase in 
both markers between day 1 and 2 and a fall on day 3. 
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Table 4.12: serum cleaved and uncleaved CK18 in the admitting, second and last day 
of patients admitted to ICU with sepsis (N=4). Mean values are given with the range 
and standard deviation (SD). The Kuskall Wallis test was used to test for a 
significant difference between levels of cleaved and uncleaved in CK18 in each 
individual patient. No significant differences were observed. 
 
 
 
 
 
 
 
 
 
 Day N CK18 
(U/L) 
Range Mean SD Kruskall 
Wallis 
cleaved 
versus 
uncleaved 
Sepsis  
(N=4) 
 1 4 Cleaved 1071.45-
1468.01 
1199.78 249.0648 0.73 
Uncleaved 896.9-
2382.84- 
1347.121 667.1293 
 2 4 Cleaved 1029.64-
2813.48 
1523.713 862.4694 0.49 
Uncleaved 449.86-
5143.977 
2441.738 2304.678 
 3 4 Cleaved 947.95-
1459.27 
1224.095 213.7419 0.39 
Uncleaved 1035.562-
1661.198 
1439.501 479.1486 
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4.3.7 Serum total HMGB1 (ng/ml) and CK-18 (U/L) cleaved and uncleaved in the 
serum of patients without Sepsis or ALD  
Serum total HMGB1 (ng/ml) was measured in patients without sepsis or ALD (N=4) 
over their stay in ICU. Patients were admitted for various reasons including cardiac 
arrest, pulmonary embolism & diabetic ketoacidosis (DKA). Samples included 
admitting (1), second (2) and last day (3). Patients had a significant elevated total 
HMGB1 (Mean 13.70ng/ml SD 6.12) on their admitting day compared to healthy 
controls (p=0.0286). They maintained a relatively similar HMGB1 level between 
days 1 to 2. (Figure 4.10 (A)) 
Serum cleaved and uncleaved CK18 (U/L) was measured in this same patient cohort 
over their stay in ICU. Patients showed a visible increases on admitting values for 
cleaved (Mean 1664.705 U/L) SD 712.606) and uncleaved (Mean 2687.94 U/L SD 
268.7) CK18 compared to healthy controls (p=0.0159 & 0.043 respectively).  There 
was a visible decrease in uncleaved CK18 between day 1 to 2 but this was not 
significant (figure 4.10 (B)). There were no significant differences between values 
for cleaved and uncleaved CK18 on any day. See table 4.13.  
 
 
 
 
 
 
 
 
 
 
 126 
 
 
 
Figure 4.10: Top (A) Line graph showing the mean (N=4) serum total HMGB1 
(ng/ml) in the admitting, second and last day of patients without ALD or sepsis. 
Means are plotted with Standard error of the mean (SEM).  X axis is the serum 
concentration of total HMGB1 (ng/ml) and Y axis is Day. Trend shows relatively 
similary serum total HMGB1 between days 1 and 2 (B) Bar chart showing the Mean 
(N=4) serum cleaved/uncleaved CK18 (U/L) in the admitting, second and last day of 
patients without ALD or sepsis. Means are plotted with SEM. A axis is serum 
concentration of cleaved/uncleaved CK18 (U/L) and Y axis day. Blue = cleaved 
CK18 & Red= uncleaved CK18. These patients exhibited higher levels of admitting 
uncleaved CK18 than cleaved. Both levels fell between day 1 and 2. 
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 Day N CK18 
(U/L) 
Range Mean SD Kruskall 
Wallis 
cleaved 
versus 
uncleaved 
Sepsis  
(N=4) 
 1 4 Cleaved 1210.5-
2712.7 
1664.705 748.69 0.73 
Uncleaved 340.282-
2600.419 
2537.459 356.30 
 2 4 Cleaved 1223.2-
1945.36 
1626.11 184.14 0.60 
Uncleaved 332.244-
6426.202 
1906.852 934.41 
Table 4.13: serum cleaved and uncleaved CK18 (U/L) in the admitting, second and 
last day of patients admitted to ICU with no ALD or sepsis (N=4). Mean values are 
given with the range and standard deviation (SD). Kuskall Wallis testing was used to 
test for a significant difference between levels of cleaved and uncleaved in CK18 in 
each individual patient. No significant differences were detected. 
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4.3.8 Comparative analysis of serum total HMGB1 (ng/ml) and serum 
cleaved/uncleaved CK18 (U/L) in patients with sepsis versus patients with no 
ALD and no sepsis.  
Serum total HMGB1 (ng/ml) was measured in patients with sepsis (N=4) and 
patients with no ALD or sepsis (N=4) over their stay in ICU. Samples included 
admitting (1), second (2) and last day (3).  Patients with sepsis had higher admitting 
levels of total HMGB1 (Mean 17.60ng/ml SD 4.21) compared with patients with no 
ALD or sepsis (Mean 13.70ng/ml SD 6.12) .This was a similar pattern for all other 
measured days (figure 4.11). This is an expected observation as HMGB1 levels are 
known to increase with sepsis, however, the difference between levels were not 
significant (table 4.10).  
Both patient groups showed fairly similar levels of cleaved and uncleaved CK18 
with no significant differences (figure 1.12 A & B).  
 
 
 
Figure 4.11: Bar chart showing the mean (N=4) serum total HMGB1(ng/ml) in the 
admitting, second and discharge day of patients with sepsis (Blue) versus patients 
without ALD or sepsis (Red). Means are plotted with Standard error of the mean 
(SEM).  X axis is the serum concentration of HMGB1 (ng/ml) and Y axis is Day. 
Patients with sepsis had higher levels of HMGB1 on both days, with an increase 
between days 1 and 2. 
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Figure 4.12: Top (A) Bar chart showing the mean serum cleaved CK18 (U/L) in 
patients with sepsis (N=4, Blue) and patients with no ALD or sepsis (N=4, Red). 
Patients exhibited fairly similar levels of serum cleaved CK18. Bottom (B) Bar chart 
showing the Mean serum uncleaved CK18 in patients with sepsis (N=4, Blue) and 
patients with no ALD or sepsis (N=4, Red). Again similar levels of uncleaved CK18 
with patients without sepsis or ALD exhibiting a fall between day 1 and 2 and the 
opposite being observed in patients with sepsis. Means of admitting, second and 
discharge days to ICU are plotted with SEM. X axis is cleaved/uncleaved CK18 
(U/L) and Y axis is the day. 
 
 
 
A 
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4.3.9 Comparative analysis of serum total HMGB1 (ng/ml) and serum 
cleaved/uncleaved CK18 (U/L) in patients with ALD and sepsis versus patients 
with sepsis. 
Serum total HMGB1 (ng/ml) was measured in patients with ALD and sepsis (N=3) 
and patients with sepsis (N=4) over their stay in ICU. Samples included admitting 
(1), second (2) and last day (3).  Patients with sepsis had higher admitting levels of 
total HMGB1 (Mean 17.60ng/ml SD 4.21) compared with patients with ALD and 
sepsis(Mean 11.17ng/ml SD 0.61) .This was a similar pattern for all other measured 
days (figure 4.11). The difference between levels was not significant (table 4.10). 
Serum total HMGB1 levels of patients with ALD and sepsis were also lower than 
patients with no ALD and no Sepsis on both days. 
Both patient groups showed fairly similar levels of cleaved and uncleaved CK18 
with no significant differences (figure 1.12 A & B) (table 4.14) 
 
 
 
Figure 4.13: Bar chart showing the mean serum total HMGB1 (ng/ml) in the 
admitting, second and discharge day of patients with ALD and sepsis (N=3,Blue) 
versus patients with sepsis (N=4,Red). Means are plotted with Standard error of the 
mean (SEM).  X axis is the serum concentration of HMGB1 (ng/ml) and Y axis is 
Day. Patients with sepsis had visibly higher concentrations of serum total HMGB1 
than patients with ALD and sepsis on all days. 
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Figure 4.14: Top (A) Bar chart showing the mean serum cleaved CK18 in patients 
with ALD and sepsis (N=3, Blue) and patients with sepsis (N=4, Red). Patients in 
both groups exhibited comparable concentrations of cleaved CK18 in all days. 
Bottom (B) Bar chart showing the Mean serum uncleaved CK18 in patients with ALD 
and sepsis (N=3, Blue) and patients with sepsis (N=4, Red). Again comparable 
concentrations of uncleaved CK18 were observed in both patient groups. Means of 
admitting, second and discharge days to ICU are plotted with SEM. X axis is the 
serum total cleaved/uncleaved CK18 in ng/ml and Y axis is the day. 
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 Day N CK18 
(U/L) 
Range Mean SD Mann 
Whitney U 
(sepsis versus 
ALD & 
sepsis) 
Sepsis  
(N=4) 
 1 3 Cleaved 1071.45-
1468.01 
1199.78 249.0648 Day 
1 
C=0.
2284 
Uncleaved 896.9-
2382.84- 
1347.121 667.1293 
 2 3 Cleaved 1029.64-
2813.48 
1523.713 862.4694 UC= 
0.662 
Uncleaved 449.86-
5143.977 
2441.738 2304.678 
 3 3 Cleaved 947.95-
1459.27 
1224.095 213.7419 Day 
2  
C=0.
2288
4 Uncleaved 1035.562-
1661.198 
1439.501 479.1486 
ALD & 
sepsis(N=3) 
 1 3 Cleaved 911.07-
1305.81 
781.883 599.0604 UC= 
0.94 
Uncleaved 1390.12-
2518.993 
1848.76 524.5204 
 2 3 Cleaved 1040.01-
1747.35 
1402.813 354.0236 Day 
3 
C= 
0.228
4 Uncleaved 1040.746-
5399.037 
2477.43 1701.286 
 3 3 Cleaved 1004-
1284.41 
1102.793 157.4872 UC=
0.226  
Uncleaved 399.977-
3490.914 
1569.71 1285.104 
Table 4.14: Table showing significance testing, using the Mann-Whitney U test, on 
serum cleaved and uncleaved CK18 (U/L) in patients with sepsis versus patients with 
ALD and sepsis. Mean values are given with the range and standard deviation (SD). 
No significant differences were observed. 
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4.3.10 Comparison of Routine biochemistry and relationship with novel 
biomarkers  
Routine clinical chemistry was collected on patients with ALD and sepsis and 
patients with sepsis alone to look for significant differences. Alanine transaminase 
(ALT) is a gold standard marker of liver dysfunction; normal levels are between 10-
40U/L
121
. Pro-thrombin time (PT) was identified by the pre-study analysis to be the 
most sensitive and specific test in this sub group of patients (patients with ALD). 
Normal range is a PT of 10-14 seconds. ALD and sepsis patients had higher ALT 
values and more prolonged PT times than patients with sepsis alone. However 
patients with Sepsis alone had higher levels of HMGB1 than patients with ALD and 
sepsis. This analysis shows that patients with more deranged liver function have 
lower concentrations of serum total HMGB1. Cleaved and uncleaved CK18 were 
similar between patient groups, despite the derangement seen in ALT and PT and 
relative differences between HMGB1. 
These differences in routine biochemistry aren’t significant, but confirms, that 
sample size is contributing to significance levels, as these differences where 
significant in the pre-study cohort (sample size was 119). (Table 4.15 & 4.16)  
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 Day N Range Mean  SD Mann Whitney U 
test 
ALD 
& 
Sepsis  
 1 3 24-88 54.67 32.1 Day 1 0.2284 
 2 3 13-74 45.3 30.7 
 3 3 31-102 69.67 35.0 Day 2  0.662 
Sepsis  1 4 26-31 36.25 17.32 
2 4 18-62 33.5 20.5 Day 3 0.8 
3 3 18-78 44.25 29.5 
Table 4.15: Table showing mean values of ALT, given with the range and standard 
deviation (SD) in patients with ALD and sepsis versus patients with sepsis. Mann 
Whitney U testing was done to test for significant differences.  
 
 Day N Range Mean  SD Mann Whitney U 
test 
ALD 
& 
Sepsis  
 1 3 14.9-25.1 21.2 5.5 Day 1 0.8 
 2 3 15-21.1 18.13 3.0 
 3 3 15.1-29.9 21.9 7.5 Day 2  0.4 
Sepsis  1 4 16.3-21.8 16.3 3.5 
2 4 14.1-28.7 18.1 6.1 Day 3 0.2 
3 3 11.9-16.2 14.1 1.7 
Table 4.16: Table showing mean values of Pro-thrombin time (PT), given with the 
range and standard deviation (SD) in patients with ALD and sepsis versus patients 
with sepsis. Mann Whitney U testing was done to test for significant differences.  
 
 
 
 
 
 
 
 
 
 
 
 
 135 
4.3.11 Summary  
HMGB1 is significantly elevated in all patients admitted to ICU compared to healthy 
controls (P<0.05). However it appears to be non-specific for sepsis, as even those 
patients who were admitted without sepsis had elevated admitting levels similar to 
sepsis patients (i.e. mean admitting serum total HMGB1 in sepsis patients 
17.60ng/ml, mean admitting serum total HMGB1 in non-sepsis and non ALD 
patients 13.70ng/ml).  
Patients with ALD as a group had lower levels of HMGB1 when compared to other 
patients admitted to ICU. Comparison between patients with decompensated ALD 
and ALD with sepsis showed that there was a mild elevation on all days that wasn’t 
significant. However, ALD and sepsis patients had lower levels of HMGB1 on all 
three days when compared to patients with sepsis alone. This indicates that patients 
with ALD potentially have an impaired ability to produce HMGB1. 
Higher concentrations of uncleaved CK18 (U/L) were observed in the serum of 
patients with decompensated ALD compared to cleaved levels, suggesting that these 
patients are undergoing significant hepatocyte loss through necrosis more than 
apoptosis. This is probably related to their presenting complaint (i.e. variceal 
haemorrhage). This difference is not statistically significant, but approaching a 
significant level (i.e. p=0.089), suggesting that perhaps sample sizes aren’t large 
enough. Patients with ALD and Sepsis and patients with sepsis alone also had higher 
concentrations of uncleaved as opposed to cleaved CK18 (U/L) indicating that either 
necrosis is the mode by which cells are being lost or apoptosis is impaired in some 
way with these patients.   
Correlation with routine chemistry shows that although other routine tests (i.e. ALT 
& PT) are significantly elevated in patients with ALD and sepsis compared to 
patients with sepsis alone, novel biomarker HMGB1 is the opposite. Lack of 
significant differences between clinical chemistry of patients with ALD and sepsis 
and patients with sepsis alone also highlights the significance of samples size. Where 
significant differences existed during the pre-study analysis where sample size was 
much larger. 
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4.4 Discussion 
4.4.1 HMGB1 in sepsis  
HMGB1’s structure and pro-inflammatory characteristics are discussed in the section 
1.2.4. Research has shown  that HMGB1 release is largely divided into two 
pathways, either active secretion by monocytes as a pro-inflammatory cytokine or 
passive release from apoptotic and necrotic cells 
122
. It has recently been 
demonstrated in RAW 264.7 macrophages that magnesium sulphate (MgSo
4
) inhibits 
the translocation of HMGB1 from the nucleus to the cytoplasm via inhibition of the 
NF-κB signalling pathway123.  
Studies have already shown that HMGB1 levels are significantly increased in 
patients with severe sepsis
29
. Research has thus far been unable to ascertain whether 
or not this is related to disease severity and outcome. Cullberg et al
124
 found that 
lower levels of HMGB1 were detected in patients with a poorer outcome compared 
to those that survived and levels in those that did survive remained elevated even 
after other cytokine levels had normalised. Persistent immune cell infiltration and 
chronic inflammation has also been noted in experimental sepsis were Gonnert et 
al
48
 found persistence of inflammatory infiltration in the liver weeks after insult. This 
persistence has been noted in other human studies
125
, but its significance has not 
been quantified.  Further studies have found that HMGB1 levels did not differ in 
survivors and non survivors of severe sepsis.
126
 This mixed picture was observed in 
patient analysis in this chapter.  
Apoptosis occurs in a wide range of cells in patients with sepsis and shock. The 
lymphoid organs and columnar epithelial cells of the gastrointestinal tract have been 
shown to be particularly vulnerable
88
 Apoptosis induces macrophages to release 
HMGB1 in vivo and administering anti-HMGB1 antibodies protect against organ 
damage but not apoptosis in the spleen
127
. In chapter 3 splenic apoptosis was found 
in an LPS model of murine sepsis and concluded to be a result of pathways involving 
adrenal corticosteroid hormone release, potentially explaining failure of anti-
HMGB1 antibodies to protect against lymphocyte apoptosis in Qin et al
127
. They also 
concluded that HMGB1 production is downstream of apoptosis on the final common 
pathway to organ damage in severe sepsis. 
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In the present study HMGB1 levels were elevated in patients who had no evidence of 
sepsis or an inflammatory process. The consensus by the ACCP/SCCM
1
 explains 
that a SIRS (i.e. inflammation) can occur as a result of non-infectious insults. It has 
been shown that HMGB1 release is an early event after traumatic injury in 
humans
128
. 
4.4.2 HMGB1 and cirrhosis  
In this study patients with ALD and sepsis had a tendency to have more deranged 
ALT and PT (table 4.15 & 4.16), however, their HMGB1 values were consistently 
lower than patients with sepsis. This indicates that there is a potential inherent 
disability in a patient with ALD’s ability to secrete HMGB1. This was further 
confirmed by the lower levels of HMGB1 seen in patients with a decompensation of 
ALD, compared to patients admitted to ICU with no ALD or sepsis (see figure 4.4 & 
4.10). 
Cirrhosis is known to be caused by a chronic inflammatory process
116
. It has been 
shown that HMGB1 serum levels are significantly higher in patients with low 
fibrosis compared to those with high fibrosis in patients with hepatitis B virus 
(HBV). This study concluded that HMGB1 is a non-invasive, repeatable, and 
convenient marker for distinguishing advanced fibrosis from low fibrosis in chronic 
HBV patients
129
. In the present analysis, patients had Child-Pugh
120
 scores of B/C 
(see table 4.4) indicating a high level of cirrhosis. So this is a probable explanation 
for the lower concentrations of HMGB1 seen in these patients.  Clinical impact of 
this is reflected where patients with cirrhosis are found to have an increased 
susceptibility to bacterial infection
130
. With respect to HMGB1 levels detected in 
cirrhotic patients in this study, it could be due to an inability to mount an effective 
inflammatory response. Furthermore, HMGB1, although not a specific marker of 
liver function, has been shown to be important in the pathogenesis of acute liver 
failure. In vivo use of anti-HMGB1 antibodies to neutralize HMGB1’s effects 
resulted in suppression of hepatic enzymes and plasma inflammatory cytokines, 
along with a marked improvement in histological findings and survival
131
. 
Acute episodes of chronic hepatitis B (CHB) represent the “acute on chronic liver 
failure” (AOCF) much like ALD patients with a sepsis. It has been shown that during 
an acute episode of CHB, an excessive immune response is triggered, and a huge 
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amount of HMGB1 can be detected in the blood. This systemic increase of HMGB1 
causes an amplified systemic inflammation and further aggravates liver injury
132
. 
4.4.3 CK18, Apoptosis and Necrosis  
All cells, including hepatocytes, require oxygen for their metabolism, most 
importantly for ATP generation. A restriction in oxygen supply results in damage to 
the cell and can lead to apoptosis or necrosis. Patients with decompensated ALD 
showed higher concentrations of uncleaved compared to cleaved CK18 in this 
analysis (see figure 4.4). Three of the four patients were admitted with variceal 
haemorrhage (a common reason for admission of cirrhotic patients
117
). During 
episodes patients haemorrhage a significant amount of blood, leading to reduced 
blood flow and perfusion of organs, which can lead to hypoxia and necrosis, and 
therefore an increased concentration of uncleaved CK18. Nanji et al
133
 stated that 
reduced oxygen levels through hypoxia is a cause of hepatocyte necrosis. Similarly, 
alcohol consumption can influence several other factors believed to be involved in 
hepatocyte necrosis, including depletion of the energy-storing molecule ATP, 
oxidative stress, and release of endotoxins.  Conversely, they stated that hepatocyte 
apoptosis was influenced by alcohol consumption through alterations to enzyme 
cytochrome P450 system, small molecules (i.e., cytokines) involved in cell 
communication, oxidative stress, and changes in iron metabolism.  
While lymphocyte apoptosis contributes to immunosuppression in sepsis, recent 
evidence suggests that necrosis of hepatocytes predominates in septic patients with 
liver dysfunction and correlates with poor survival
134
.  Hofer et al
135
 found that 
serum total CK18 concentrations were significantly elevated in patient’s not 
surviving sepsis. Further analysis showed no differences of the biomarkers between 
survivors and non-survivors when liver function was retained. Importantly, however, 
significantly higher levels of uncleaved CK18 were observed in the non-surviving 
group with decreased liver function. They concluded that, unlike apoptosis, 
hepatocyte necrosis is an early predictor of disease outcome in septic patients with 
liver dysfunction. Furthermore, the loss of parenchymal cells due to necrosis may be 
the primary mode of cell death in these patients. The current analysis showed that all 
patients with sepsis with and without ALD had visibly elevated levels of uncleaved 
compared to cleaved CK18 (figure 4.14 A&B). These levels were similar between 
patient groups (ALD & sepsis and patients with sepsis alone) despite patients with 
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ALD and sepsis having higher concentrations of serum ALT and prolonged PT (table 
4.15 & 4.16). Post-mortem analysis of patients dying from severe sepsis showed 
significant levels of apoptosis and lobular necrosis in the liver parenchyma
91
.   
It’s difficult to define the mechanisms contributing to the increase of uncleaved 
CK18 in patients with sepsis, as apoptosis is known to be impaired. Meaning, those 
elevations look could look exacerbated and augmented by a reduction in apoptosis.  
4.4.5 Summary and further research  
In the present study, HMGB1 and cleaved/uncleaved CK18 have been identified as 
markers of sepsis in the defined patient groups. They were significantly elevated in 
patients admitted to ICU compared with healthy controls. Analysis of HMGB1 was 
shown to be elevated in patients with sepsis and having an underlying liver disease 
seems to impair its release (as reflected by lower serum levels in ALD and ALD & 
sepsis patients). This is probably due to the chronic inflammatory process related to 
cirrhosis
129
. 
Uncleaved CK18 was also found to be a reliable marker of necrosis in these patients, 
and in keeping with the literature, highlighted the significant, emerging role that 
necrosis has to play in patients with sepsis. Furthermore, in patients with 
decompensated ALD (particularly those with variceal haemorrhage) uncleaved CK18 
was elevated, indicating a possible use as a marker of severity in these patients.   
In future work Bonferroni correction of the P values should be carried out to correct 
for multiple testing, furthermore, these preliminary results require validation in larger 
patient cohorts in order to increase statistical power.  As discussed, HMGB1 can 
exist as acetylated and oxidised sub forms depending on mode of cell death. Further 
investigation may show visible differences in concentrations between patient groups 
and may reflect a further difference in concentrations of sub forms. Cleaved and 
particularly uncleaved CK18, are proving in the literature, to be reliable markers of 
hepatocyte necrosis (patients with elevated LFTs had significantly higher levels of 
uncleaved CK18 and poorer outcome
135
). This is reflected partially in the current 
study and further work could help quantify and clarify the significance of necrosis 
and apoptosis in patients with sepsis. 
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Chapter 5: 
General discussion 
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5 General discussion  
Sepsis is a significant problem in the United Kingdom. Diagnosis, management and 
prognosis are proving difficult for clinicians. This is further exacerbated by the lack 
of sensitive and specific biomarkers for the disease, and complications related with it 
(i.e. organ dysfunction).  The lack of biomarkers and efficacious therapeutic 
intervention is a result of inadequate understanding of this disconnect between 
murine and human sepsis on a molecular level and in vivo.  
5.1 Understanding in vitro pathways of inflammation and their 
limitations  
By comparing two different immune cells from murine (RAW 264.7) and human 
donors (THP1), responses to LPS and the inflammatory signalling pathway could be 
compared through the detection of the p65 subunit of NFκB, a common pathway for 
the production of de novo cytokines such as TNF-α. The differences in response to 
LPS on a molecular level explain why there is an apparent disconnect between 
murine and human sepsis on an in vivo level (see Chapter 2). The major findings of 
chapter 2 were: 
1. P65 is a reliable, detectable and reproducible way of measuring activation of 
the NFκB pathway in human and murine immune cell lines. 
2. Activation of the NFκB pathway (via TLR 4) by in vitro dosing with LPS 
represents a dose-response relationship. 
3. Human cells respond to lower concentrations of LPS than murine cells.  
4. Human cells had a higher overall increase in nuclear p65 compared with 
murine cells.  
5. Murine cells show a molecular resilience to LPS dosing, but when activated 
become very sensitive to changes in concentration. 
One hour was chosen as a time point as activation of the p65 pathway is known to 
take a short time
80
. A major limitation of this study was that it only looked at a single 
time point. In future work it is hoped to look at a time course in order to ascertain 
whether or not high doses reflect the maximum activation of the pathway. Also 
further analysis is needed in order to investigate how the activation of the pathway 
translates to cytokine production. 
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5.2 Understanding in vivo models of sepsis and their limitations 
More robust models are superseding the LPS model of endotoxaemia in mice, and 
histopathological analysis of the faecal inoculation model has shown it to be more 
representative of the gradual rising and sustaining response cytokine response, as 
oppose to boom and bust seen with LPS (see Chapter 3). The major findings of 
chapter 3 were: 
1. LPS use in vivo represents a technique for inducing sterile information and 
doesn’t meet the ACCP/SCCM1 definition of sepsis. 
2. Both models (LPS and faecal inoculation) showed principal changes 
consistent with neutrophil recruitment into tissues; LPS animals had a 
tendency to show greater numbers of neutrophils than the faeces dosed 
animals. This is probably related to the higher concentrations of cytokines 
that are seen with the LPS model
8
. 
3. Faecal inoculated animals demonstrated occasional recruitment of neutrophils 
into adipose tissue and skeletal muscle (although still minimal, to a greater 
extent than LPS animals). This reflects the diffuse systemic recruitment seen 
in human sepsis and highlights the superiority of this model in recapitulating 
a human sepsis environment in vivo. 
Further analysis is needed in order to identify whether or not the histopathological 
changes seen in the tissues are reflected in serum cytokine levels. Furthermore, a 
time-course investigation of the progressive nature of both models is needed.  
5.3 New biomarkers and their translatability 
 HMGB1 and cleaved/uncleaved CK18 have been shown to be accurate ways of 
monitoring the level of inflammation, necrosis and apoptosis in vitro and in vivo
4, 35, 
55, 122, 125
. Their application to defined groups of ICU patients, who could potentially 
benefit from them, has shown that there is potential for a clinical application (see 
chapter 4). Their use alongside currently used markers of liver function could 
enhance the overall picture that clinicians have when approaching these patients. 
However, further research is needed involving larger sample sizes and more 
scrupulous statically analysis before widespread application can occur. The major 
findings of this chapter were: 
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1. HMGB1 and cleaved/uncleaved CK18 can be used as markers of sepsis in the 
defined patient groups; 
2. They were significantly elevated in all patients admitted to ICU compared 
with healthy controls. 
3. HMGB1 is markedly elevated in patients with sepsis; however having an 
underlying condition, such as ALD, impairs its release. 
4. Uncleaved CK18 was found to be a reliable marker of necrosis and 
highlighted the significance of necrosis in septic patients.  
5. Patients with decompensated ALD (secondary to variceal haemorrhage) may 
benefit from measuring uncleaved CK18 as a measurement of severity of 
disease. 
6. Using HMGB1 and CK18 alongside routine biochemistry can enhance the 
potential “liver profile” available to clinicians and help in diagnosis, 
treatment and prognosis of patients with sepsis. 
5.4 Sepsis, translational medicine & the future  
Figure 5.1 describes the process of translational science in the development of 
effective biomarkers and treatments in the study of sepsis. Understanding the cellular 
signalling pathways involved in the development of an inflammatory response and 
the differences between human and murine cells, leads to the development of 
effective, representative models of sepsis in mice. This allows for reliable, valid in 
vivo studies to be done in order to develop a model of sepsis that is closest to that of 
the human condition. The final step is the development of effective, efficacious 
treatment based on these reliable models. This thesis has shown that the bridge 
between in vivo and human models is the most significant hurdle to overcome in the 
cross between laboratory science and clinical medicine.  
Dieterle et al
136
, published a landmark paper on the first formal qualification of 
safety biomarkers for regulatory decision making and the application of biomarkers 
to drug development with regards to the kidney. They summarize the Predictive 
Safety Testing Consortiums (PSTC) biomarkers submission, analyses and 
conclusions, and then go on to discuss the new standards and optimal practices 
identified through the qualification review process at the Food and Drug Agency 
(FDA) and the European Medicines Agency (EMEA). Looking at this paper as a 
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translational model, they have provided guidance and a framework that could be used 
for future biomarker qualifications (i.e. HMGB1 and CK18). 
 
 
 
 
 
Figure 5.1: Translational model for research in sepsis. Effective In vitro and in vivo 
systems that are representative of humans, will lead to the development of 
biomarkers such as HMGB1 and CK18 which can prove efficacious in the treatment 
and diagnosis of disease. 
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VII Appendix I 
Below is an Index of all histopathological analysis of organs from each animal. 
Animals are indexed by their case number, and this is given along with the study 
number, intervention and a summary of the major histological findings from each 
individual tissue. 
Case No Animal Treatment/ 
cull 
Tissue Histology 
Samples from the University of Liverpool 
12L-
1393 
1 25mg/kg 
LPS; 6h 
Heart NHAIR 
Lung Capillaries and veins packed with NL (and monocytes?), 
activation of endothelial cells (EC), some NL rolling on 
arterial walls 
Liver No glycogen (NG; PAS), but often one to several smaller, 
well delineated vacuoles in hepatocytes; small NL aggregate 
in parenchyma and mild increase in individual NL between 
hepatic cords (HC); several NL in central and portal veins 
(CV, PV) [PHOTO] 
Pancreas NHAIR; interstitial vein with numerous NL 
Kidney NHAIR 
Spleen Mod. sized follicles with several apoptotic cells; red pulp with 
mod. cellularity and numerous apoptotic cells 
Thymus Numerous apoptotic cells, in particular in cortex [PHOTO] 
BM Mod. cellularity, some apoptotic cells 
Brain NHAIR; several NL in capillaries, occ. packed [PHOTO] 
MG NHAIR (mainly L) 
EF NHAIR 
BF NHAIR 
Skin NHAIR (no fat included) 
12L-
1394 
2 25mg/kg 
LPS; 6h 
Heart NHAIR 
Lung Numerous NL in vessels and capillaries, with some NL 
rolling 
Liver NG (PAS); increased number of individual and small groups 
of NL between HC; some NL rolling in CV and PV 
Pancreas NHAIR 
Kidney NHAIR 
Spleen Mod. sized follicles with several apoptotic cells; red pulp with 
low cellularity, numerous apoptotic cells and some NL 
aggregates [PHOTO] 
BM Mod. cellularity, some apoptotic cells 
Brain NHAIR; some NL in veins 
MG NHAIR 
EF NHAIR, apart from focal extensive acute haemorrhage 
BF NHAIR 
Skin NHAIR; small veins in sc fat partly packed with NL 
12L-
1395 
3 25mg/kg 
LPS; 6h 
Heart NHAIR 
Lung Often numerous NL in veins and capillaries, partly packed, 
with some NL rolling 
Liver NG (PAS); increased number of individual and small groups 
of NL between HC; some NL rolling in CV and PV 
Pancreas NHAIR 
Kidney NHAIR 
Spleen Mod. sized follicles with some apoptotic cells; red pulp with 
very low cellularity, some apoptotic cells and some NL 
Thymus Numerous apoptotic cells, in particular in cortex 
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Popl. ln NHAIR 
BM Mod. cellularity; occ. apoptotic cell 
Brain NHAIR; some leptomeningeal veins with numerous NL 
MG NHAIR 
EF NHAIR 
BF NHAIR; small veins with numerous NL 
Skin NHAIR (hardly any fat) 
12L-
1396 
4 25mg/kg 
LPS; 6h 
Heart NHAIR 
Lung Often numerous NL in veins and capillaries, partly packed, 
with some NL rolling 
Liver NG (PAS); mildly increased number of individual and small 
groups of NL between HC; some NL rolling in CV and PV 
Pancreas NHAIR 
Kidney NHAIR 
Spleen Mod. sized follicles with several apoptotic cells; red pulp with 
mod. cellularity and numerous apoptotic cells 
Thymus Numerous apoptotic cells, in particular in cortex 
BM Mod. cellularity; occ. apoptotic cell 
Brain NHAIR; some NL in veins 
MG NHAIR 
EF NHAIR; small veins with numerous NL 
BF NHAIR 
12L-
1397 
5 25mg/kg 
LPS; 6h 
Heart NHAIR 
Lung Often numerous NL in veins and capillaries, partly packed, 
with some NL rolling 
Liver Patchy aggregates of hepatocytes with glycogen, else NG 
(PAS); mildly increased number of individual and small 
groups of NL between HC; some NL in CV and PV 
Pancreas NHAIR 
Kidney Focal interstitial mononuclear infiltration, otherwise NAIR 
Brain NHAIR; several NL in veins, some rolling 
Spleen Rel large secondary? follicles with numerous apoptotic cells; 
red pulp with mod. cellularity and numerous apoptotic cells 
and NL 
Thymus Numerous apoptotic cells, in particular in cortex 
BM High cellularity; occ. apoptotic cell 
MG NHAIR 
EF NHAIR 
BF NHAIR; small veins with numerous NL [PHOTO] 
Skin Dermal and sc vessels often with numerous NL [PHOTO] 
12L-
1398 
6 25mg/kg 
LPS; 6h 
Heart NHAIR 
Lung Often numerous NL in veins and capillaries, often packed, 
with some NL rolling 
Liver NG (PAS); mildly increased number of individual and small 
groups of NL between HC 
Pancreas NHAIR 
Kidney NHAIR 
BM High cellularity; occ. apoptotic cell 
MG NHAIR 
EF NHAIR 
PF NHAIR 
Skin NHAIR, one sc vein with several NL 
12L-
1399 
7 25mg/kg 
LPS; 6h 
Heart NHAIR;  a few NL attached to EC in atrium 
Lung Often numerous NL in veins and capillaries, often packed, 
with some NL rolling 
Liver NG (PAS); mod. increased number of individual and 
scattered larger groups of NL (with necrotic hepatocytes) 
between HC  
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Kidney NHAIR 
Brain Several NL in small veins 
Spleen Mod sized follicles with numerous apoptotic cells; red pulp 
with mod. cellularity and numerous apoptotic cells 
Thymus Very numerous apoptotic cells, in particular in cortex 
Ln Small follicles and T cell zones, no apoptotic cells 
BM High cellularity; occ. apoptotic cell 
MG NHAIR (mainly L) 
EF NHAIR; veins with several NL  
Skin NHAIR 
12L-
1400 
8 25mg/kg 
LPS; 6h 
Heart NHAIR 
Lung Often numerous NL in veins and capillaries, with some NL 
rolling 
Liver Mod number of hepatocytes with glycogen, patchy (PAS); 
mod. increased number of individual and scattered larger 
groups of NL between HC  
Kidney NHAIR 
Brain NHAIR 
Spleen Mod sized follicles with mod. number of apoptotic cells; red 
pulp with mod. cellularity and some apoptotic cells and 
numerous NL 
Thymus Mod number of apoptotic cells, in particular in cortex 
BM High cellularity; occ. apoptotic cell 
MG NHAIR (mainly L) 
EF Mild multifocal mononuclear (LC, PC, mØ) infiltration, some 
NL in vein 
PF NHAIR 
Skin NHAIR; veins with numerous NL 
12L-
1401 
9 25mg/kg 
LPS; 6h 
Heart NHAIR 
Lung Small veins often packed with NL, also numerous in arteries, 
with some NL rolling and EC activation; mild focal alveolar 
haemorrhage [PHOTO] 
Liver Scattered hepatocytes with glycogen (PAS); increased 
number of individual and very small groups of NL between 
HC, some NL in CV and PV  
Kidney NHAIR 
Brain NHAIR 
Spleen Rel large follicles with a few apoptotic cells; red pulp with 
low cellularity and occ. apoptotic cells and several NL 
Thymus Rel. numerous apoptotic cells, in particular in cortex 
BM High cellularity; occ. apoptotic cell 
MG NHAIR (mainly L) 
EF NHAIR, apart from several veins with numerous NL, some 
rolling? [PHOTOS] 
BF NHAIR 
Skin NHAIR 
12L-
1402 
10 25mg/kg 
LPS; 6h 
Heart NHAIR 
Lung Small veins often packed with NL, also numerous in arteries, 
with some NL rolling and EC activation [PHOTO] 
Liver NG (PAS); increased number of individual and some small 
groups of NL with occ. necrotic hepatocyte between HC, 
some NL in CV and PV, occ. rolling [PHOTO]  
Kidney Glomerula with occ. homogenous eosinophilic material in 
tufts (PAS: slightly pos.) [PHOTO] 
Spleen Mod sized follicles with several apoptotic cells; red pulp with 
low cellularity and some apoptotic cells  
Thymus Numerous apoptotic cells, in particular in cortex 
BM Mod cellularity; some apoptotic cells 
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MG NHAIR 
EF NHAIR 
BF NHAIR 
Skin NHAIR 
12L-
1403 
11 25mg/kg 
LPS; 6h 
Lung Small veins with numerous NL, partly packed, with some NL 
rolling 
Liver NG (PAS); mildly increased number of individual and occ. 
group of NL with necrotic hepatocyte between HC, some NL 
in CV and PV 
Kidney NHAIR 
Brain NHAIR 
Spleen Mod sized follicles with several apoptotic cells; red pulp with 
low cellularity and several apoptotic cells and NL 
BM Mod cellularity; some apoptotic cells 
MG NHAIR 
EF NHAIR 
BF NHAIR 
Skin NHAIR 
12L-
1404 
12 Inter-
peritoneal 
saline 
(control); 6h 
Heart NHAIR 
Lung NHAIR 
Liver Diffuse glycogen (DG; PAS); one small mixed cellular 
aggregate 
Kidney Occ. tubular and glomerular protein casts; otherwise NHAIR 
Spleen Rel small follicles with a few apoptotic cells; cell rich red 
pulp 
Thymus A few disseminated apoptotic cells, in particular in cortex 
BM High cellularity 
MG NHAIR (mainly L), apart from the presence of NL in lumen 
of vessels and occasionally immediately outside capillary 
EF NHAIR, apart from the presence of numerous NL in lumen of 
vessels 
BF Focal attachment of bacteria and debris (from faeces 
suspension) with NL aggregates to serosa; numerous vessels 
with NL in lumen 
12L-
1405 
13 Inter-
peritoneal 
saline 
(control); 6h 
Heart NHAIR 
Lung NHAIR [PHOTO] 
Liver DG (PAS); NHAIR [PHOTO] 
Kidney NHAIR 
Spleen Rel small follicles; cell rich red pulp [PHOTO] 
Thymus Occ. apoptotic cell in cortex [PHOTO] 
BM High cellularity 
MG NHAIR 
EF NHAIR 
Skin NHAIR 
12L-
1406 
14 Inter-
peritoneal 
saline 
(control); 6h 
Heart NHAIR 
Lung NHAIR 
Liver DG (PAS); NHAIR 
Kidney NHAIR 
Spleen Rel small follicles; cell rich red pulp 
Thymus Occ. apoptotic cell in cortex 
BM High cellularity 
MG NHAIR 
EF NHAIR 
BF NHAIR 
Skin NHAIR; ln. with a few NL in lumen of vessels and in medulla 
12L-
1407 
15 Inter-
peritoneal 
saline 
Heart NHAIR (cross section) 
Liver DG (PAS); NHAIR 
Kidney NHAIR 
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(control); 6h Spleen Rel small follicles; cell rich red pulp 
Thymus Occ. apoptotic cell in cortex 
BM High cellularity 
MG NHAIR  
EF NHAIR, apart from the presence of several NL in lumen of 
vessels 
Skin NHAIR, apart from the presence of numerous NL in lumen of 
vessels 
12L-
1408 
16 Inter-
peritoneal 
saline 
(control); 6h 
Heart NHAIR 
Lung NHAIR 
Liver DG (PAS); NHAIR, apart from scattered small NL aggregates 
with occ. necrotic hepatocyte 
Kidney NHAIR 
Spleen Mod sized, partly secondary follicles, often with several 
apoptotic cells; cell rich red pulp 
Thymus Some disseminated apoptotic cells in cortex 
BM High cellularity 
MG NHAIR 
EF, peri-
renal fat 
NHAIR, apart from the presence of several NL in lumen of 
vessels in perirenal fat and focal macrophage infiltration in 
EF 
BF NHAIR, apart from focal extensive acute haemorrhage 
Skin NHAIR (very small section) 
12L-
1409 
17 Inter-
peritoneal 
saline 
(control); 6h 
Heart NHAIR 
Lung NHAIR 
Liver DG (PAS); NHAIR, apart from scattered small NL aggregates 
with occ. necrotic hepatocyte 
Kidney NHAIR 
Spleen Mod sized, partly secondary follicles, with some apoptotic 
cells; cell rich red pulp 
Thymus Some disseminated apoptotic cells in cortex 
BM High cellularity 
MG with 
fat 
Presence of several NL in lumen of vessels and multifocal 
mild to mod NL infiltration (focal neutrophilic interstitial 
myositis and steatitis) 
Skin NHAIR 
12L-
1410 
18 350mg/kg 
APAP; 6h 
Heart NHAIR 
Lung NHAIR, apart from scattered apoptotic alveolar epithelial 
cells 
Liver NG (PAS), but delineated cytoplasmic vacuoles in 
hepatocytes, often larger centrilobular; scattered centrilobular 
apoptotic/necrotic hepatocytes; occ. NL in central vein and 
occ. a few leukocytes in adjacent  sinuses 
Kidney NHAIR 
Spleen Mod sized, partly secondary follicles, with numerous 
apoptotic cells; cell rich red pulp with numerous apoptotic 
cells 
BM High cellularity; a few apoptotic cells 
MG NHAIR  
EF NHAIR 
BF NHAIR (perirenal, subcutaneous) 
Skin NHAIR 
12L-
1411 
19 350mg/kg 
APAP; 6h 
Heart NHAIR 
Lung NHAIR, apart from scattered apoptotic cells (where?) 
Liver NG (PAS), but delineated cytoplasmic vacuoles in 
hepatocytes, larger centrilobular (1-2 cell layers, hydropic 
degeneration); scattered centrilobular apoptotic/necrotic 
hepatocytes; a few NL and some activated EC (?) in central 
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veins [PHOTO] 
Kidney NHAIR 
Spleen Rel small follicles, with numerous apoptotic cells; cell rich 
red pulp with numerous apoptotic cells [PHOTO] 
Thymus Numerous apoptotic cells, in particular in cortex [PHOTO] 
BM High cellularity; some apoptotic cells 
MG NHAIR  
EF NHAIR 
BF NHAIR 
Skin NHAIR 
12L-
1412 
20 350mg/kg 
APAP; 6h 
Heart NHAIR 
Lung NHAIR 
Liver NG (PAS), but delineated cytoplasmic vacuoles in 
hepatocytes; centrilobular cell loss and hydropic 
swelling/degeneration of remaining hepatocytes [Grade 2] 
[PHOTO] 
Kidney NHAIR 
Spleen Rel small follicles with numerous apoptotic cells; cell rich red 
pulp with numerous apoptotic cells 
Thymus Numerous apoptotic cells, in particular in cortex 
BM High cellularity; some apoptotic cells 
MG NHAIR 
EF NHAIR, apart from focal mononuclear infiltrate (ln.?) 
BF NHAIR 
Skin NHAIR 
12L-
1413 
21 350mg/kg 
APAP; 6h 
Heart NHAIR 
Lung NHAIR 
Liver NG (PAS), but delineated cytoplasmic vacuoles in 
hepatocytes; centrilobular cell loss and hydropic 
swelling/degeneration of remaining hepatocytes [Grade 2-3] 
Kidney NHAIR 
Spleen Rel small follicles with very numerous apoptotic cells; cell 
rich red pulp with numerous apoptotic cells 
Thymus Very numerous apoptotic cells, in particular in cortex 
BM High cellularity; some apoptotic cells 
MG NHAIR 
EF NHAIR 
BF NHAIR 
Skin NHAIR 
12L-
1414 
22 350mg/kg 
APAP; 6h 
Heart NHAIR 
Lung NHAIR 
Liver NG (PAS), but delineated cytoplasmic vacuoles in 
hepatocytes; centrilobular cell loss and hydropic 
swelling/degeneration of remaining hepatocytes [Grade 2-3] 
Kidney NHAIR 
Spleen Rel small follicles with very numerous apoptotic cells; cell 
rich red pulp with numerous apoptotic cells 
Thymus Numerous apoptotic cells, in particular in cortex 
BM High cellularity; a few apoptotic cells 
MG NHAIR 
EF NHAIR, apart from the presence of several NL in lumen of 
vessels and some outside vessels 
BF NHAIR 
Skin NHAIR, apart from focal mononuclear infiltration in subcutis 
12L-
1415 
23 350mg/kg 
APAP; 6h 
Heart NHAIR 
Lung NHAIR 
Liver NG (PAS), but delineated cytoplasmic vacuoles in 
hepatocytes; centrilobular cell loss and hydropic 
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swelling/degeneration of remaining hepatocytes [Grade 1-2] 
Kidney NHAIR 
Spleen Rel small follicles with numerous apoptotic cells; cell rich red 
pulp with several apoptotic cells 
BM High cellularity; numerous apoptotic cells 
MG NHAIR 
EF NHAIR 
BF NHAIR 
Skin NHAIR 
Samples from the University of Jena  
12L-
1073 
1 Inter-
peritoneal 
saline 
(control); 6h 
Liver Diffuse glycogen (DG), most pronounced centrilobular 
(PAS); NHAIR 
MG NHAIR (mainly L) 
EF NHAIR 
PF NHAIR 
SF NHAIR (with skeletal muscle, NHAIR) 
12L-
1074 
2 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); NHAIR, apart 
from small random focal leukocyte aggregate 
MG NHAIR (mainly L) 
EF NHAIR 
PF NHAIR 
SF NHAIR 
12L-
1075 
3 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); NHAIR 
MG NHAIR (mainly L) 
EF NHAIR 
PF NHAIR 
SF NHAIR, with larger artery exhibiting activated (?) endothelial 
cells (EC) 
12L-
1076 
4 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); focal area of 
coagulative necrosis with a few leukocytes (NL); two random 
focal leukocyte aggregates 
MG NHAIR (mainly L) 
EF NHAIR 
PF NHAIR 
SF NHAIR 
12L-
1077 
5 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); NHAIR 
MG NHAIR (mainly L) 
EF NHAIR 
PF NHAIR, apart from small focal subserosal LC aggregate 
SF NHAIR (with skeletal muscle, NHAIR) 
12L-
1078 
6 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); NHAIR 
MG NHAIR 
EF NHAIR 
PF NHAIR 
SF NHAIR, apart from a small loose focal aggregates of mØ 
12L-
1079 
7 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); one small focal 
aggregates of 5-6 NL beside central vein (CV); occasionally a 
few leukocytes in CV 
MG NHAIR (mainly L) 
EF NHAIR 
PF NHAIR 
SF Some arteries with mild EC activation; a few leukocytes in 
lumen of small veins; slight multifocal PC/LC infiltration 
(with skeletal muscle, NHAIR) 
12L-
1080 
8 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); scattered random 
small focal leukocyte aggregates 
MG NHAIR (mainly L) 
EF NHAIR 
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PF NHAIR 
SF NHAIR 
12L-
1081 
9 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); NHAIR 
MG NHAIR (mainly L) 
EF NHAIR, apart from focal subserosal LC aggregate 
PF NHAIR 
SF Focal, poorly delineated area with small vessel EC activation 
and mild to moderate perivascular and interstitial mixed 
cellular (mØ, fewer NL and LC) infiltration 
12L-
1082 
10 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); NHAIR, apart 
from one random focal leukocyte aggregate 
MG NHAIR (mainly L) 
EF NHAIR 
PF NHAIR 
SF NHAIR 
12L-
1083 
11 Inter-
peritoneal 
saline 
(control); 6h 
Liver DG, most pronounced centrilobular (PAS); scattered random 
small leukocyte aggregates, one focal large area of LC 
infiltration around a CV 
MG NHAIR (mainly L) 
EF NHAIR 
PF NHAIR, apart from marked multifocal acute interstitial 
haemorrhage 
SF NHAIR 
12L-
1084 
12 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver DG, most pronounced centrilobular (PAS); multifocal patchy 
subserosal NL infiltration and focal attachment of bacteria 
and debris (from faeces suspension) to serosa; a few to 
several NL in the lumen of CVs and portal veins (PV) 
MG NHAIR (mainly L), apart from the presence of NL in lumen 
of vessels and occasionally immediately outside capillary 
EF NHAIR, apart from the presence of numerous NL in lumen of 
vessels 
PF Focal attachment of bacteria and debris (from faeces 
suspension) with NL aggregates to serosa; numerous vessels 
with NL in lumen 
SF NHAIR, apart from the presence of numerous NL in lumen of 
vessels 
12L-
1085 
13 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver DG (variable intensity; PAS); subserosal (multifocally) one 
layer of NL infiltration; several NL in the lumen of CVs and 
PVs and a few in sinusoids immediately outside CV 
MG NHAIR (mainly L), apart from the presence of some NL in 
lumen of vessels 
EF NHAIR, apart from the presence of numerous NL in lumen of 
vessels 
PF Focal subserosal LC aggregate; attachment of bacteria and 
debris (from faeces suspension) with NL to serosa; several 
vessels with NL in lumen 
SF NHAIR, apart from the presence of occasional NL in lumen 
of vessels 
12L-
1086 
14 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver Mutifocal patchy (sub)serosal NL infiltration, partly with 
fibrin/cell debris and bacteria (from faeces suspension); 
several NL in the lumen of CVs and PVs; DG, most 
pronounced centrilobular (PAS) 
MG NHAIR (mainly L) 
EF NHAIR, apart from the presence of numerous NL in lumen of 
vessels 
PF Focal attachment of bacteria and debris (from faeces 
suspension) with NL and blood to serosa; vessels with NL in 
lumen 
SF NHAIR, apart from the presence of NL in lumen of vessels 
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12L-
1087 
15 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver Slight focal subserosal NL infiltration; several NL in the 
lumen of CVs and PVs and a few in sinusoids immediately 
outside CV; DG (variable intensity, PAS) 
MG NHAIR (mainly L), apart from the presence of some NL in 
lumen of vessels 
EF NHAIR, apart from the presence of several NL in vessels 
PF NHAIR, apart from the presence of some NL in lumen of 
vessels 
SF NHAIR, apart from the presence of some NL in lumen of 
vessels 
12L-
1088 
16 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver Slight focal subserosal NL infiltration; several NL in the 
lumen of CVs and PVs and a few in sinusoids immediately 
outside CV; DG (variable, but generally reduced intensity, 
PAS) 
MG NHAIR (mainly L), apart from the presence of several NL in 
lumen of vessels 
EF NHAIR, apart from the presence of numerous NL in lumen of 
vessels 
PF Focal attachment of NL with bacteria and debris (from faeces 
suspension) to serosa and (sub)serosal infiltration by mØ and 
NL; vessels with numerous NL in lumen 
SF NHAIR, apart from the presence of often numerous NL in 
lumen of vessels 
12L-
1089 
17 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver Subserosal (multifocally) one layer of NL infiltration and 
focal attachment of NL with debris and bacteria (from faecal 
suspension); several NL in the lumen of CVs and PVs and a 
few in sinusoids immediately outside CV; DG (variable 
intensity, reduced amount, PAS) 
MG NHAIR (mainly L), apart from the presence of a few NL in 
lumen of vessels 
EF NHAIR, apart from the presence of NL in lumen of some 
vessels and slight focal subserosal LC infiltration 
PF NHAIR, apart from the presence of NL in lumen of vessels 
SF NHAIR, apart from the presence of several NL in lumen of 
vessels and focal mild perivascular LC infiltrate 
12L-
1090 
18 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver Subserosal (multifocally) one layer of NL infiltration and 
focal attachment of NL with debris and bacteria (from faecal 
suspension), in one subserosal area focal hepatocellular 
coagulative necrosis; several NL in the lumen of CVs and 
PVs and a few in sinusoids immediately outside CV; DG 
(variable intensity, reduced amount, PAS) 
MG NHAIR (mainly L), apart from the presence of a few NL in 
lumen of vessels 
EF NHAIR, apart from the presence of NL in lumen of vessels 
PF NHAIR, apart from the presence of NL in lumen of vessels 
SF NHAIR, apart from the presence of NL in lumen of vessels 
12L-
1091 
19 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver Multifocal (sub)serosal NL infiltration (very superficial), 
often with attached NL with fibrin and bacteria (from faeces 
suspension); several NL in the lumen of CVs and PVs; DG 
(variable intensity, reduced amount, PAS) 
MG NHAIR (mainly L), apart from the presence of a few NL in 
lumen of vessels 
EF NHAIR, apart from the presence of some NL in lumen of 
vessels 
PF NHAIR, apart from the presence of some NL in lumen of 
vessels 
SF NHAIR, apart from the presence of several NL in lumen of 
vessels 
12L- 20 1.75 mL/kg Liver A few (sub)serosal NL; some NL in the lumen of CVs and 
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1092 body weight 
stool 
suspension; 
6h 
PVs; DG (variable intensity, PAS) 
MG NHAIR (mainly L) 
EF NHAIR, apart from the presence of a few NL in lumen of 
vessels 
PF NHAIR 
SF NHAIR, apart from the presence of a few NL in vessels 
12L-
1093 
21 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver Multifocal mild (sub)serosal NL infiltration (very superficial), 
occasionally attached NL with fibrin and bacteria (from 
faeces suspension); several NL in the lumen of CVs and PVs; 
DG (variable intensity, reduced amount, PAS) [PHOTOS] 
MG Apart from the presence of several NL in the lumen of a 
larger artery, NHAIR (mainly L); no rolling! [PHOTOS] 
EF NHAIR, apart from the presence of some NL in lumen of 
vessels[PHOTOS] 
PF Focal serosal NL infiltration with some bacteria; vessels often 
with a few NL in lumen [PHOTOS] 
SF NHAIR, apart from the presence of several NL in lumen of 
vessels [PHOTOS] 
12L-
1094 
22 1.75 mL/kg 
body weight 
stool 
suspension; 
6h 
Liver Multifocal mild (sub)serosal NL infiltration (very superficial), 
occasionally attached NL with fibrin and bacteria (from 
faeces suspension); several NL in the lumen of CVs and PVs 
and a few in sinuses immediately adjacent to CV; DG 
(variable intensity, reduced amount, PAS) 
MG NHAIR (mainly L), apart from the presence of several NL in 
lumen of vessels 
EF NHAIR, apart from the presence of numerous NL in lumen of 
vessels 
PF NHAIR, apart from the presence of some NL in lumen of 
vessels and focal attachment of a small amount of NL with 
debris and bacteria to the serosa 
SF NHAIR, apart from the presence of numerous NL in lumen of 
vessels 
* MG – Musculus gastrocnemius; EF – epididymal fat; BF – brown fat; SF – subcutaneous 
fat; BM – bone marrow (sternum, femoro-tibial joint); NHAIR – no histological abnormality 
is recognised; L – longitudinal section; NL – neutrophils, LC – lymphocytes, mØ – 
macrophages . 
